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1. Introduction 
 
1.1. Haematopoiesis and development of blood cellular 
components 
 
1.1.1. Human haematopoiesis  
 
  Haematopoiesis is the development of the blood cellular components. 
Vertebrate haematopoiesis occurs in two phases: The first phase is a transient 
embryonic (“primitive”) phase and this phase is followed by the definitive (“adult”) 
phase. These two phases of vertebrate haematopoiesis differ in their sites of blood 
cell production, the timing of haematopoiesis, the morphology of the cells 
produced, and even the type of globin genes used in the red blood cells (Fig.1.1.1).  
  Human haematopoiesis begins in the yolk sac during the first weeks of 
embryonic development. The embryonic phase of haematopoiesis is used to 
initiate the cell circulation that provides the embryo with its initial blood cells. This 
also helps to begin the flow of cells with its capillary network to the yolk sac. A 
dense population of blood cells is present and niched onto the ventral side of the 
aortic endothelium in human embryo. The studies in mammalian embryos 
demonstrate that the first complex multilineage lymphopoietic progenitors and HSC 
activities are autonomously generated within the intraembryonic para-aortic 
splanchnopleura /aorta–gonad–mesonephros region (PAS/AGM region) in the 
absence of the yolk sac.1 This population of cells is specific for surface antigens 
and expression of genes that generally characterize the primitive progenitors.2-4  
  These intra-embryonic precursors have been implicated to play a fundamental 
role in the migration of  the liver, enterprising of human definitive hematopoiesis5,6 
and initiation of a haematopoietic cell differentiation program.7 The definitive phase 
of haematopoiesis is used to generate more differentiated and effecter cell types 
that loose the specific progenitor surface antigens with several courses of somatic 
cell divisions and differentiation.  
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Figure 1.1.1: The figure illustrates the mammalian embryonic haematopoietic development 
and the adult haematopoietic hierarchy
1
 (figure adapted from Dzierzak E et al, 2002). The 
progressive appearance of composite activities (left) leads to the appearance of HSCs with a long-
term multilineage repopulation capacity of the entire haematopoietic system. The adult 
haematopoietic hierarchy (right), shows all differentiated haematopoietic lineages arising from 
HSCs. These HSCs self-renew (shown in the blue box) and differentiate in a unidirectional manner 
in a normal state individual. However, recent data in several experimental systems suggested that 
small dedifferentiation steps might occur in stem cells crossing lineage boundaries8,9  
 
This phase of haematopoiesis also provides the pool of the stem cells with 
amazing self renewal capacity that lasts for the lifetime of the individual.1  Different 
functionally specialized mature blood cells are derived from a common primitive 
progenitor cell. In haematopoietic system this population is called the stem cells 
(HSCs). It has been estimated that there is approximately 1 stem cell per 105 bone 
marrow cells.10  
 These stem cells represent a self-renewing population of cells (immature 
progenitors) and a potential to differentiate to become committed cells (mature 
progenitor), and finally to a short term lived and definitive effecter blood cell. HSCs 
self-renew and differentiate in a unidirectional manner in a normal state individual. 
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Recent data in several experimental systems has shown that small 
dedifferentiation steps can occur in stem cells and the lineage boundaries can be 
crossed.8,9 
 
1.1.2. Classification of human haematopoietic stem cell  
 
Human haematopoietic stem cells (hHSCs) are rare small mononuclear cells 
that tend to be noncycling or to have long cell cycles. They divide to form more 
hHSCs (self-generation or symmetric division) or commit to form the different 
haematopoietic lineages (asymmetric division)11-16 Asymmetric cell division (ACD) 
in HSCs has been reported to make HSCs fate decisions. These immature 
progenitors are committing to lymphocyte progenitor formation (common lymphoid 
progenitors, CLPs) or to the formation of myeloid progenitors (common myeloid 
progenitors, CMPs). CMPs are large blast cells that can then form megakaryocyte- 
erythroid progenitors (MEPs) committed to the formation of erythroid and 
megakaryocytic cell lineages. CMPs can also form more restricted granulocyte-
macrophage progenitors (GMPs) that are able to generate granulocytic, 
macrophage, and eosinophil progenitors. These lineage-restricted cells can 
generate respective mature lineage populations. 17-20  
In the haematopoietic system, the pluripotent HSC resides at the top of the 
haematopoietic hierarchy. Pluripotent stem cells are the descendants of totipotent 
cells and can differentiate into nearly all cells21 i.e. the cells derived from any of the 
three germ layers (ectoderm, endoderm and mesoderm). A primitive 
haematopoietic cell that gives rise to erythrocytes, neutrophils, basophils, 
eosinophils, platelets, mast cells, monocytes, tissue macrophages, osteoclasts, 
and the T and B lymphocytes is coined as a “multipotential haematopoietic stem 
cell”. Because of the very short life span of most effecter-cells, mature blood cell 
production is an ongoing process, with the production of 1.5x106 blood cells every 
second in an adult human. This high turnover rate necessitates some homeostatic 
control mechanisms; the primary level of which resides with the HSCs.  
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  Stem cells undergo two types of cell division: Symmetric and asymmetric. 
Symmetric division gives rise to two identical daughter cells both gifted with stem 
cell properties. Asymmetric division, produces two cells with one as stem cell and 
the second one as a progenitor cell with limited self-renewal potential.22 In an 
alternative theory, the stem cells remain undifferentiated due to environmental 
prompt in their particular niche. Differentiation occurs only when they leave that 
niche or no longer receive environmental signals. Studies in Drosophila germarium 
have identified the signals dpp and adherens junctions that prevent germarium 
stem cells from differentiating.23 24  
Homeostasis of haematopoietic stem cells is a tightly regulated process, 
controlled by intrinsic and extrinsic signals. Although a variety of molecules 
involved in HSC maintenance and self-renewal are known, it remains unclear how 
robust HSC homeostasis is achieved. There is an enormous proliferative and 
developmental capacity of the more committed multipotent, oligo-potent and 
lineage-restricted progenitor cells within the haematopoietic hierarchy. A significant 
degree of homeostatic control of mature blood cells is also mediated at the level of 
these progenitors.25 
 
1.1.3. The haematopoietic colony forming cell (CFC) 
 
A single cell from the bone marrow is capable of forming many different kinds 
of colonies composed of erythrocytes (E), granulocytes (G), and platelet 
precursors. This cell is called the colony forming unit (CFU). This type of cell has 
also been called the CFU-GEMM (multipotent stem cell), the colony-forming unit 
for granulocytes, erythrocytes, macrophages, and megakaryocytes (Fig.1.1.3) and 
is able to self renew.  
The CFU that can reside in the spleen and form a colony are called CFU-S. 
The colony-forming unit–spleen (CFU–S) depends on the ability of infused bone 
marrow cells to give rise to clones of maturing haematopoietic cells in the spleens 
of irradiated mice after 8 to 12 days. It is used to measure more mature progenitor 
or Transit Amplifying Cells rather than stem cells.26 From HSC to mature blood 
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cells, extensive proliferation and expansion occurs that results in the production of 
millions of blood cells. Multi-potential progenitors (e.g. CFU-GEMM) and lineage-
committed 
 
Figure 1.1.3: Hierarchal presentation of colony forming cells in hHSCs. The above figure 
illustrates the nature of colony forming cells in human haematopoiesis. Stem cell division and 
differentiation is a procedure that continuously takes place to replenish the various lymphoid, 
myeloid and erythroid-megakaryocyte lineages and also to maintain a small pool of HSC with the 
self-renewal capacity that is capable of carrying on haematopoiesis. From HSC to mature blood 
cells, extensive proliferation and expansion occurs that results in the production of millions of blood 
cells. Multi-potential progenitors (e.g. CFU-GEMM) and lineage-committed progenitors (e.g. CFU-E, 
CFU-GM), representing various stages along the differentiation pathway with various differentiation 
and proliferation potentials, can be identified by in vitro assays and by the expression of known 
surface antigens. 
 
progenitors (e.g. CFU-E, CFU-GM), representing various stages along the 
differentiation pathway, with various differentiation and proliferation potentials, can 
be identified by in vitro assays and by the expression of known surface antigens.  
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The first multi-potential haematopoietic stem cell is the CFU-M, L. The CFU-M, 
L gives rise to the CFU-S and the several lymphocytic stem cell types. The 
immediate progeny of the CFU-S, however, are lineage- restricted stem cells. Each 
can produce only one type of cell in addition to renewing itself. The BFU-E (burst-
forming unit, erythroid), is a lineage-restricted stem cell formed from the CFU-S. 
The above CFUs are based on the lineage in which they differentiate after plating 
in methylcellulose culture. The colony-forming unit–spleen (CFU–S) was the basis 
of an in vivo clonal colony formation, which depends on the ability of infused bone 
marrow cells to give rise to clones of maturing haematopoietic cells in the spleens 
of irradiated mice after 8 to 12 days. It is considered to be a measure of more 
mature progenitor or Transit Amplifying Cells rather than stem cells. 
 
1.1.4. The haematopoietic inductive microenvironments. 
 
Regions of determination of colony forming units (CFUs) such as spleen and 
bone marrow are referred to as haematopoietic inductive microenvironments 
(HIMs). In early blood cell formation (in the mesoderm surrounding the mammalian 
yolk sac), the endothelial cells of the blood islands appear to be heterogeneous 
HIMs, inducing the stem cells to form different blood and lymphocyte lineages.27 
Haematopoietic stem cells require the BM microenvironment, which regulates their 
migration, proliferation, and differentiation in order to maintain active 
haematopoiesis throughout life.28,29  
 
1.1.5. Homing, engraftment and repopulation of hHSCs 
 
Homing is a swift process in which circulating haematopoietic cells actively 
cross the blood/BM endothelium barrier and lodge transiently in the BM 
compartment by activation of adhesion interactions prior to their proliferation. Stem 
cells normally home to bone marrow, but can also migrate to spleen in case of 
alarm situations and do not require cell division, while engraftment does.  
Many cell types, including long-term repopulating stem cells, expressing 
hCD34+CD38-  surface markers, short-term repopulating progenitors, expressing 
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hCD34+CD38+ surface markers and mature, specialized T cells and neutrophils, 
can home to the BM. 30,31 The only stem cells, which can home to their endosteal 
niches, initiate long-term repopulation. The murine BM homing cells, which 
successfully adhere to the recipient stroma, are viable due to protection from 
apoptosis. Lineage negative immature cells (Lin-) demonstrate stronger adhesion 
properties (30-fold) than lineage positive cells 32,33.  
 Engraftment and repopulation: Short-term engraftment (ranging from weeks 
to a few months) is initiated by differentiating progenitors. Durable long-term 
multilineage engraftment (many months in mice, and years in patients) is carried 
out by stem cells following their unique homing to their specialized niches.34 Growth 
factors play an important role in initiating signal transduction pathways, altering 
transcription factors; these in turn activate genes determining the differentiation of 
blood cells. Prestimulation of human cord blood (CB) CD34+ cells with stem cell 
growth factor (SCF) induces surface CXC chemokine receptor 4 (CXCR4; CD184) 
expression and the appearance of cycling G1 hCD34
+CD38+ cells (short term 
repopulating cells). This in turn creates an increased production of the proteolytic 
enzyme matrix metalloproteinase 9 (MMP9) and stromal cell derived factor-1(SDF-
1) directed migration and homing to the bone marrow and spleen of NOD/SCID 
mice that have received the transplant .35-37  
 
1.1.6. Sources of haematopoietic stem cells 
 
 Bone Marrow: The classic source of HSCs is the bone marrow. About 1 in 
every 100,000 cells in the marrow is a long-term, blood-forming stem cell; other cells 
present include stromal cells, stromal stem cells, blood progenitor cells, and mature 
and maturing white and red blood cells. 
 Peripheral Blood: For clinical transplantation of human HSCs, cells are 
preferably harvested from peripheral circulating blood. These are essential CD34+ 
enriched population of cells. 
 Umbilical cord blood cells: The blood within the umbilical cord, known as 
cord blood, is a rich and readily available source of primitive, undifferentiated stem 
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cells (of type CD34+ and CD38-). These cord blood cells can be used for bone marrow 
transplant. Embryonic stem cells: Embryonic Stem (ES) cells are pluripotent stem 
cells. They are able to differentiate into all derivatives of the three primary germ 
layers: ectoderm, endoderm, and mesoderm. 
 
1.1.7. Human cord blood CD34+ cells 
 
The majority of human cells with repopulating cell activities have been 
identified as CD34+ cells. The hCD34 over expression experiments in 
haematopoietic cells have indicated its role in cell adhesion and inhibition of 
haematopoiesis. Haematopoiesis in CD34 knockout mice appears unaffected; 
however knock-out embryos contain 2-3 times fewer CFUs than normal controls. 
38 Enriched human CB CD34+CD38- cells, home successfully to the murine BM 
and spleen. They show long term repopulation capacity and have homing 
capabilities. The CD34+ human bone marrow cells contain the vast majority of 
long term-HSCs, as well as primitive myeloid and lymphoid progenitors.39  
 
1.2. Developmental pathways in human haematopoiesis 
 
1.2.1. Long term-HSCs in xenotransplant models 
 
The long-term reconstitution potential of human HSCs has been described in 
SCID mouse repopulating assays. In the most advanced xenotransplant models 
by utilizing the Rag2 and IL-2R  double-deficient mouse40 or the NOD/SCID 
IL2R  deficient mouse.41 The CD34+CD38- or the CD34+CD90+ fractions of 
human bone marrow and cord blood have been shown to reconstitute all human 
hematolymphoid lineage cells for a long term, indicating that these CD34+ 
fractions contains normal human HSCs. An injection of at least 1000 cells of the 
human CD34+CD38- bone marrow cells is required to obtain multi-lineage, long-
term reconstitution in xenotransplant models. The percent of hCD34+CD38- or 
hCD34+CD90+ cells that are multipotent, long-term HSCs is still difficult to 
determine in a engraft model. 
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1.2.2. The subsets of human lymphoid and myeloid progenitor. 
 
 The existence of lymphoid-committed progenitors in the human bone marrow 
with the hCD34+CD38+CD45RA+CD10+ phenotype has been reported.42 In 
human cord blood, common lymphoid progenitors (CLP) activity is found in the 
CD7+ fraction of CD34+CD38-CD45RA+ population. The hCD34+CD38-
CD45RA+CD7+ population do not exist in the adult bone marrow.43 IL-7R , a 
critical marker for the murine CLP, is expressed in human hCD10+ CLPs in the 
bone marrow, but not in hCD7+ CLPs in the cord blood.  These data suggest 
that the CLP phenotype and the requirement of IL-7 signaling might have 
changed during the human ontogeny. In the myelo-erythroid pathway, CMP, GMP 
and MEP subsets can be isolated from the hCD34+CD38+ fraction in both the bone 
marrow and cord blood (Manz et al., 2002). All these fractions of cells are negative 
for the early lymphoid markers hCD10, hCD7 or hIL-7R . These myelo-erythroid 
progenitors can be prospectively isolated according to the expression of 
hCD45RA and hIL-3R . CD45RA-hIL-3R lo (CMPs), hCD45RA+hIL-3R lo (GMPs) 
and hCD45RA-hIL-3R - (MEPs) efficiently form distinct myelo-erythroid colony 
types according to their definitions (Fig.1.1.2). CMPs give rise to MEPs and 
GMPs in vitro, and a significant proportion of CMPs possess clonal GM and 
MegE potentials.44 Thus, the hierarchical myeloid progenitor relationships 
demonstrated in mice is well preserved in human haematopoiesis.  
 Phenotypic comparisons between mouse and human subsets show that 
CD34, a marker positive only for murine CMPs and GMPs, is uniformly expressed 
on all three human subsets, and that the Fc RII/III (CD16/CD32), marking 
murine CMPs and GMPs, was not detectable in any  of the human myeloid 
progenitors 44 All haemato/lymphoid progenitors develop from CD34+CD38- HSC 
population 41but themselves have no self-renewal activity in xenogenic 
transplantation models 45, indicating that they are downstream of human LT-
HSCs in both the bone marrow and the cord blood.  
 Flt3 shows a significant difference in its distribution in human and mouse 
hematopoiesis. This suggests a critical role of Flt3 signaling in hematopoietic 
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development in humans. hFlt3 is expressed in leukemic blasts in most cases with 
acute myelogenous leukemia (AML)46,47 (Carow et al., 1996; Rosnet et al., 1996), 
and FLT3 is one of the most frequently mutated genes in AML.48,49 The signal 
from FLT3 mutations should be controlled under the regulation of normal Flt3  
 
Figure 1.2.2: A model of the haematopoietic developmental hierarchy. Self-renewing HSCs 
reside at the top of the hierarchy, thereby giving rise to a number of multipotent progenitors. 
Multipotent progenitors give rise to oligo-potent progenitors including the CLP, which gives rise to 
mature B lymphocytes, T lymphocytes, and natural killer (NK) cells. The common myeloid 
progenitor (CMP) gives rise to granulocyte-macrophage progenitors, which differentiate into 
monocytes/macrophages and granulocytes, and megakaryocyte/erythrocyte progenitors, which 
differentiate into megakaryocytes/platelets and erythrocytes. The cell surface phenotype of many 
of these cell types is shown for the murine and human systems 50(Figure adapted from Bryder D 
et al., 2006). 
 
 expression machinery, signaling from FLT3 mutations should involve HSCs and 
GMPs, both of which are critical targets for leukemic transformation in mouse 
AML models.51-54 Thus, special considerations are required in utilizing mouse 
models to understand the role of FLT3 mutations in human leukemogenesis. 
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  Further phenotypic and functional characterization of human hematopoietic 
cells should be performed by utilizing improved efficient xenotransplant models. 
These approaches will eventually help to identify LSCs that should be a critical 
cellular target in leukemia treatment.55 
  1.2.2. Lineage-Bias in HSCs 
 
 Using limiting dilution strategies combined with other streamlined experimental 
and statistical methods for examining HSCs at the clonal level, HSCs fall into three 
distinct lineage-biased clusters.56-58 These are quantitatively defined by the ratio “?” 
of lymphoid to myeloid cells that the HSC generates upon differentiation (which 
makes ñ a peripheral predictor for the clonal association of a reconstituted 
haematopoietic system). Balanced HSCs repopulate peripheral white blood cells in 
the same ratio of myeloid to lymphoid cells as seen in unmanipulated mice (on 
average about 15% myeloid and 85% lymphoid cells, or 3?ñ?10), in the NOD/SCID 
mice. Myeloid-biased (My-bi) HSC give rise to too few lymphocytes resulting in 
ratios 0<?<3, whereas lymphoid-biased (Ly-bi) HSC generate too few myeloid 
cells, which results in lymphoid-to-myeloid ratios of 10<?<00. All three types are 
normal HSCs in the sense that they have self-renewal capacity and can regenerate 
all haematopoietic lineages (pluripotency).  
The lineage-bias is preserved through multiple rounds of serial 
transplantation. Balanced HSC self-renew to give rise to daughter HSC that are 
also balanced, My-bi HSC give rise to My-bi daughter HSC, and Ly-bi produce 
Ly-bi daughter HSC. There is no precursor-progeny relationship between the 
three types of HSC and they do not represent stages of differentiation. Rather, 
these are three classes of HSC, each with an epigenetically-fixed differentiation 
program. 
 
1.3. Extrinsic and intrinsic factors effecting haematopoiesis 
 
1.3.1. Cytokines  
 
The production of haematopoietic cells is under the tight control of a group of 
haematopoietic cytokines. These cytokines are glycoprotein that are normally 
present in the human blood circulation in very low (pico-molar) doses. Some of 
the known cytokines that were validated by trail in humans are: erythropoietin 
Introduction 
 17 
 
(EPO), granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF) and 
interleukin-11(IL-11).59,60  
Some of the cytokines for example, G-CSF, granulocyte-macrophage colony 
GM-CSF, interleukin-3 (IL-3), monocytic colony stimulating factor (MCSF), SCF 
and interleukin-6 (IL-6) are found to have proliferative effects on granulocyte 
colony formation61 (Fig.1.3.1) Individual cytokines can be lineage specific or can 
regulate cells in multiple lineages, and for some cell types, such as stem cells or 
megakaryocyte progenitors, the simultaneous action of multiple cytokines is 
required for proliferative responses. Cytokines exert their action through high-
affinity receptors on the cell surface that are linked to pathways of cellular 
activation, commitment, differentiation, survival, proliferation and differentiation. 
Cross-linking of receptor subunits on the outside of the cell wall leads to 
adjoining of kinases associated with the intracellular receptor tails, either as 
intrinsic activities, or because of pre-association of secondary kinase molecules. 
This intracellular association of signaling molecules results in phosphorylation of 
tyrosine residues in the receptor tail and binding of further signaling molecules that 
have phospho-tyrosine-binding domains. Several aspects of the downstream 
intracellular pathways of cytokines are similar, because different activated receptor 
cytoplasmic domains often bind a common signaling molecule or family of signaling 
molecules. Thus stoichiometry and rate of reaction are important regulatory 
influences that allow discrimination between signaling processes with different 
outcomes (Molecular cell biology. Lodish, Harvey F. 5.  ed. ) 
 
 1.3.2. Cooperative Interaction of Cytokines  
 
For efficient in vitro proliferation and differentiation, pluripotent and multi-
potent progenitor cells require a combination of cytokines [e.g. SCF, IL-1, IL-3, IL-
6, GM-CSF, and colony stimulating factor-1, (CSF-1)]. Immature haematopoietic 
cells have been shown to co-express a number of different lineage specific 
receptors at low levels. As these immature cells develop, they lose receptors for  
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Figure 1.3.1: The above figure illustrates the three types of action of haematopoietic cytokines 
62
(Figure taken from Metcalf, D. Blood 2008). (A) Lineage restricted. (B) Action on multiple 
lineages; broken line shows actions only at high concentrations. (C) Sequential actions; SCF acts on 
stem and early erythroid progenitors, while EPO acts on more mature precursors. The notion of 
sequential actions was later found to be incorrect. 
 
some cytokines e.g. SCF and IL-3, while retaining receptors for later acting 
cytokines such as CSF-1. 
Eventually immature cells reach the stage of the committed progenitor cell, 
where their proliferation and differentiation are along one particular lineage, 
guided by the lineage-restricted cytokines. Synergy occurs between some late-
acting lineages restricted cytokines such as CSF-1, EPO and G-CSF, with early 
acting cytokines such as SCF and IL-3, in stimulating the proliferation and 
differentiation of multi-potent cells. This provides a mechanism by which the 
tightly regulated changes in the level of a late acting cytokine can be coupled to 
the channelling of multi-potent progenitor cells into a lineage to satisfy the 
demand for differentiated cells. The underlying mechanism of synergy may lie at 
the level of either the receptors or at the level of post receptor signaling pathways 
(Molecular cell biology. Lodish, Harvey F. 5. ed. ) 
The action of cytokines may be autocrine, paracrine, and endocrine. Cytokines 
are critical to the development and functioning of both the innate and adaptive 
immune response, although not limited to just the immune system. They are often 
secreted by immune cells that have encountered a pathogen, thereby activating 
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and recruiting further immune cells to increase the system's response to the 
pathogen. Cytokines are also involved in several developmental processes during 
embryogenesis. 
1.3.3. Tyrosine kinase receptor and cell signalling 
 
Many cytokines such as CSF-1, SCF and FL are homodimeric that share 
some sequence homology and are structurally similar to one another. These 
three cytokines/ growth factors have complex patterns of expression due to 
alternative mRNA splicing. This allows them to be expressed as either 
membrane-spanning, cell-surface or secreted glycoproteins. All three growth 
factors are widely expressed in all tissues and two of them, SCF and CSF-1, also 
affect non-haematopoietic as well as haematopoietic cells.  
The receptors for the above cytokines are members of the platelet derived 
growth factor (PDGF) receptor family. Each receptor possesses an extra-cellular 
domain, consisting of a five immunoglobulin (Ig) like repeat. These repeats are: a 
heavily glycosylated with N-linked sugars, a trans-membrane domain, intra-
cellular domains containing a juxta-membrane region, a src-related tyrosine 
kinase domain that is interrupted by a kinase insert domain, and a carboxy-
terminal tail. The three amino terminal Ig-like domains incorporate the ligand 
binding domains of the SCF and CSF-1 receptors. Binding of this type of dimeric 
receptor to its cognate ligand stabilizes the non-covalent association between the 
two chains of the receptor at the cell surface and permits the trans-
phosphorylation of the intra-cellular domain of one chain by the other.   
Tyrosine phosphorylation in response to cytokine binding is not restricted to 
those proteins that are stably associated with the receptor. Regions containing 
tyrosines that are phosphorylated as a consequence of receptor activation act as 
docking sites for src-homology region 2 (SH2) domains of signaling and adaptor 
proteins. These proteins in turn may interact with plasma membrane associated 
proteins. An example is the association of recruited Grb2/Sos with Ras, which 
leads to their activation. The associated proteins may themselves become 
tyrosine phosphorylated. Many of the signaling pathways activated by SCF, CSF-
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1 and flat-3 ligand (FL) receptors, including the Ras/Raf-mitogen activated protein 
kinase cascade, the janus kinase (JAK)/ signal transducers and activators of 
transcription (STATs) pathway, Src family members and phosphatidylinositol-3-
kinase (PI3K), are shared.  
All three receptors are likely to exhibit ligand induced, Cbl-mediated 
decreases in receptor expression. The SCF and CSF-1 receptors are encoded by 
the proto-oncogenes c-kit and c-fms, respectively. The oncogenes derived from 
these two proto-oncogenes are present in mutated forms in retroviruses that 
cause sarcoma in cats. The mutations in the receptor genes cause constitutive 
activation of the receptors in the absence of cytokines, thus contributing to 
unregulated cell proliferation.  
 
1.3.4. The role of transcription factors 
 
Nuclear transcription factors are essential for stem cell lineage commitment. 
HSCs express a great diversity of transcripts, including a wide range of genes 
originally believed to be restricted to more mature and lineage-committed cell 
types. The single-cell polymerase chain reaction strategies had suggested that 
such loose transcription of lineage-associated transcripts was necessary to prime 
primitive progenitor cells for differentiation toward downstream fates.63  
An alternative interpretation is that stem cells possess global transcriptional 
accessibility and that it is the step-wise restriction of locus accessibility that 
underlies lineage specification.64,65 Cell fate can also be switched from one 
committed cell type to another on over expression of IL2R or GM-CSF receptors 
17,18 GATA-166 or C/EBP /ß.67 An additional mechanism of lineage specification 
has been revealed which attributes to the ablation of the transcription factors 
Pax5 or GATA-1 in lineage-restricted progenitors. This was sufficient to despecify 
their B-cell and erythroid fate, respectively, and allow a multilineage 
developmental potential.  
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Figure 1.3.4a: A complex signal transduction pathway is shown in the picture above. This 
pathway involves changes of protein-protein interactions inside the cell, induced by an external 
signal (figure taken from Molecular cell biology. Lodish, Harvey 5 ed).The production of 
mature blood cells from HSC requires three distinct genetic programs. These 
include: (a) the specification of HSC, (b) their self-renewal and c)  
 
their commitment/ proliferation/ differentiation. Most of the studies leading to the 
knowledge of genes involved in HSC genetic programs have been carried by 
assaying haematopoietic cells from animals deficient for the gene of interest. 
More recently, expression profiling strategies have been used to determine 
genetic and molecular signatures of HSC.68,69 Genes involved in deciding fate of 
HSCs during early embryogenesis include: SCL and Rbtn2/Lmo-2, which are 
necessary for primitive and definitive haematopoiesis.70,71 GATA-2 and AML1 are 
specifically required for definitive haematopoiesis.72  
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Some other factors appear to be more lineage-specific in action such as 
GATA-3, Ikaros, PU.1, GATA-1, CBP, Atf4, c-myb, and E2A, and their absence 
affects specific haematopoietic lineages. 73-77 The genetic factors involved in 
regulating fetal liver HSC are: Meis1, which is highly expressed in fetal liver Sca-1 
+ Lin- cells that are enriched for HSC activity78 and Hoxb4, which causes in vivo 
and ex vivo expansion of HSC when constitutively expressed. 79,80 Hox proteins 
interact with another transcription factor Pbx1, which itself interacts with Meis1 
and forms a trimeric nuclear complex which is involved in target gene 
regulation81,82 (Fig.1.3.4a).  
HSC self- renewal maintenance in adult BM is regulated by a different set of 
genes. A number of recent studies point out to nuclear factors such as the 
Polycomb (PcG) genes Bmi-1 and Rae-28, GATA-2 and TEL for potentially 
regulating this process. It has been observed that Bmi-1 levels decline during 
haematopoietic development, and that Bmi-1 deficient mice develop hypocellular 
BM and die at less than 2 months of age. This led to the speculation that Bmi-1 is 
involved in maintenance of the HSC pool.83 Rae-28, a known nuclear partner of 
Bmi-1, also plays a crucial role in maintaining the activity of HSCs during fetal 
haematopoiesis. 84 
The zinc-finger transcription factor GATA-2, a member of GATA family, plays 
a critical role in maintaining the pool of multipotent progenitors and HSCs, both 
during embryogenesis and in the adult.85 The zinc-finger transcription factors 
GATA-1 and its transcriptional cofactor called Friend of GATA-1 (FOG-1), have 
been found to be essential for erythroid and megakaryocytic differentiation.86,87 
PU.1 is a member of the Ets family of transcription factors and is essential in the 
development of cells of the monocytic, granulocytic and lymphoid lineages.88 
Many growth factors (CSF, GCSF, GMCSF, FLT3, TPO,IL-6, IL-3, IL-11 etc.) 
bind to receptors at the cell surface and stimulate cells to progress through the cell 
cycle and divide. Several of these receptors are kinases that start to phosphorylate 
themselves and other proteins when binding to a ligand. This phosphorylation can 
generate a binding site for a different protein and thus induce protein-protein 
interaction. In the figure, the ligand called epidermal growth factor (EGF) binds to  
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Figure 1.3.4b: Above figure is a simple illustration of basal transcription regulation mediated 
by general transcription factors (GTFs) in a eukarayotic cell (Figure adapted from Essential 
cell biology E-2). To begin transcription, eukaryotic RNA polymerase II requires the general 
transcription factors. These transcription factors are called TFIIA, TFIIB, and so on. (A) The 
promoter contains a DNA sequence called the TATA box, which are located 25 nucleotides away 
from the site where transcription is initiated. (B) The TATA box is recognized and bound by 
transcription factor TFIID, which then enables the adjacent binding of TFIIB. (C) For simplicity the 
DNA distortion produced by the binding of TFIID is not shown. (D) The rest of the general 
transcription factors as well as the RNA polymerase itself assemble at the promoter. (E) TFIIH uses 
ATP to pry apart the double helix at the transcription start point, allowing transcription to begin. 
TFIIH also phosphorylates RNA polymerase II, releasing it from the general factors so it can begin 
the elongation phase of transcription. As shown, the site of phosphorylation is a long polypeptide tail 
that extends from the polymerase molecule.  
 
the receptor (called EGFR). This activates the receptor to phosphorylate itself. The 
phosphorylated receptor binds to an adaptor protein (GRB2), which couples the 
signal to further downstream signaling processes. One of the signal transduction 
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pathways that are activated is called the mitogen-activated protein kinase (MAPK) 
pathway.  
The signal transduction component labelled as "MAPK" in the pathway was 
originally called "ERK," so the pathway is called the MAPK/ERK pathway. The 
MAPK protein is an enzyme, a protein kinase that can attach phosphate to target 
proteins such as the transcription factor MYC and, thus, alter gene transcription 
and, ultimately, cell cycle progression. Many cellular proteins are activated 
downstream of the growth factor receptors (such as EGFR) that initiate this signal 
transduction pathway (Fig.1.3.4b). Some signaling transduction pathways respond 
differently depending on the amount of signaling received by the cell. For instance, 
the hedgehog protein activates different genes, depending on the amount of 
hedgehog protein present. Complex multi-component signal transduction pathways 
provide opportunities for feedback, signal amplification, and interactions inside one 
cell between multiple signals and signaling pathways. 
 
 
1.4. Role of Hox and non-homeobox genes in haematopoiesis 
 
1.4.1. The structure of HOXB4 and its co factors. 
 
The mammalian HOX genes are the master regulators of developmental 
processes such as embryogenesis and hematopoiesis. The complex arrangement, 
regulation and co-factor association of HOX has been an area of intense research, 
particularly in cancer biology. The mammalian class I homeobox (HOX) gene 
network consists of 39 genes organized in four clusters (AD) on four separate 
chromosomes (Human; 7p14-15, 17q21-22, 12q12-13 and 2q31-37 and Mouse; 
6C2, 11B4, 15F2 and 2C3 respectively) 
The canonical HOX gene consists of two exons with one intron that ranges in 
size from 200 bases to several kilobases. The 180 bp homeobox sequence is 
located within a GC-rich region of the second exon and encodes a 60 amino acid 
DNA-binding motif, the homeodomain. The best characterized co-factors of HOX 
are the mammalian pre-B cell leukaemia homeobox (Pbx)89 and the myeloid  
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Figure 1.4.1: Schematic representation of conservation of the mammalian HOX gene network 
from Drosophila Hom-C depicting preferential binding of Pbx to paralog groups 1-10 and 
Meis to paralog groups 9-13 
90
(Figure taken from McGonigle GJ et al., 2008). Downstream Enh 
(Enhancer) sequences and upstream GCR (global control region) elements thought to control global 
expression of individual clusters are represented.  
 
ecotropic viral insertion site (Meis)91 family members (Fig.1.4.1). All of them are the 
members of the TALE (three amino acid loop extension) family of homeodomain 
proteins encoded by Class II non-clustered homeobox genes.92 
The founding members of the two best characterised TALE subfamilies, namely 
Pbx1 and Meis1 interact preferentially with 3' or 5' Hox proteins respectively 93 
trimeric Hox-Pbx-Meis complexes have also been reported 94 The. Pbx/Hox 
heterodimers bind to the consensus TGAT (T/G) NA (T/C) with the Hoxproteins 
binding to (T/G) NA (T/C) and the Pbx binding to the 5? TGAT. The Meis1 
consensus binding site (TGACAG) is followed by an AbdB-like Hox binding site 
TTA (C/T) GAC. It is predicted that Hox, Pbx and Meis1 proteins interact within 
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multiprotein complexes that have the highest level of specificity in terms of DNA 
binding and co-ordination of activation or repression events. 82  
 
1.4.2. The expression of HOX in haematopoietic cells  
 
 HOX genes are highly expressed in primary haematopoietic stem cells (HSCs) 
and in haematopoietic progenitors (HPCs) in a characteristic pattern. For example 
HOX genes such as HOXB4 or HOXA10 are highly expressed in primitive 
haematopoietic cells but silenced in more differentiated cells. Similar expression 
patterns have been observed in cells originating from both foetal and adult tissues 
and in an embryonic stem cell model of haematopoietic differentiation 
(References). Self-renewal of HSCs and HPCs may be HOX-dependent while 
inappropriate HOX expression may underlie leukaemia stem cell maintenance. 95-97 
Experimental murine transplantation models using retroviral gene transfer to 
over express the HOX gene of interest have provided detailed insight into the 
function of individual HOX genes: HOXB3 over expression resulted in 
haematological anomalies that included reduced B and T-cell differentiation and a 
delayed increase in myeloid progenitor numbers.98 HOXA10 over expression also 
resulted in reduced B-cell differentiation but without affecting the T-cell 
compartment. In addition HOXA10 over expression resulted in a marked increase 
in megakaryocyte blast colony-forming progenitor production at the expense of 
macrophage colony formation.99,100  
The majority of HOXA10 recipient mice succumbed to leukaemia after a long 
latency period (19-50 weeks). Perhaps the most surprising finding in this 
experimental system was that over expression of HOXB4 did not induce overt 
haematological anomalies, but resulted in an enhanced HSC regeneration (~50-
fold) compared to controls as demonstrated by serial transplantation. Increased 
HSC self-renewal is a common feature of several over expressed HOX genes; 
however lack of leukaemic transformation appears to be unique to HOXB4.101  
 
1.4.3. The TALE homeodomain protein family PBX 
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PBX1 is a homeodomain protein that functions in complexes with other 
homeodomain-containing proteins to regulate gene expression during development 
and/or differentiation processes. PBX is a member of the PBC protein family. The 
human PBX1 protein was initially identified as the chromosome 1 participant of the 
t(1;19) translocation, which occurs in 25 % of paediatric pre-B cell acute 
lymphocytic leukaemia which creates a chimeric gene designated E2A-PBX1.102  
  The mechanism by which E2A-PBX1 causes leukaemia is still unclear. 
However, the structure of the fusion protein, in which the majority of PBX1, 
including the homeodomain, is fused to the transcriptional activation domain of 
suggests that the oncogenic properties of E2A-PBX1 result from inappropriate 
regulation of target genes, of which the expression during haematopoiesis is 
normally regulated by wild-type PBX proteins.103,104 In vitro and in vivo data 
suggest that PBX functions in combination with heterologous homeodomain 
proteins, including class I HOX proteins. As HOX cofactors, PBC proteins improve 
HOX specificity due to the increased size of the cooperative binding site and the 
strength of DNA binding sites by different groups of HOX proteins.89,93  
In addition, cooperative DNA binding with PBC proteins may act to change the 
regulatory signal of HOX proteins, from repressors to activators.78 PBX proteins 
appear to function as part of large nucleoprotein complexes. The interactions within 
these complexes are probably decisive factors that allow the DNA binding proteins 
to discriminate among target regulatory elements. How these complexes are 
regulated during either early embryonic development or cellular differentiation of 
somatic cells to control gene expression is still unclear. Abramovich et al. (2000) 
speculated that the characterization of additional PBX-interacting proteins might 
shed light on the mechanism of PBX function, and specifically sought to identify 
novel cofactors or modifiers of PBX1.105 Although the PBX homeodomain protein is 
thought to function as a transcription factor, its mechanism of action is still 
unknown. 
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1.4.4. The novel haematopoietic PBX-interacting protein (HPIP) 
 
 The identification of novel proteins which regulate human stem cells and early 
progenitor cell fate decisions is one of the major goals for experimental and clinical 
haematology. Recently, a novel human protein, the haematopoietic PBX-
interacting protein (HPIP) that interacts with the homeobox gene and HOX co-
factor PBX1 was identified.105  
 The new haematopoietic PBX-interacting protein (HPIP) was identified by a 
yeast two-hybrid screen of a fetal-liver haematopoietic cDNA library using PBX1 as 
bait. HPIP cDNA encodes a novel protein of 731 amino acid residues containing no 
homology to any known protein and has a calculated molecular mass of 80 kDa. 
HPIP is predicted to have a coiled-coil domain, suggesting that it interacts with 
other proteins. HPIP can bind to different members of the mammalian PBX family, 
inhibit the binding of PBX1/Hox complex to DNA and block the transcriptional 
activity of E2A-PBX1. The expression of PBX1 and HPIP was characterized 
observed by reverse transcription-PCR analysis of RNA obtained from bone 
marrow: HPIP expression was detected in the CD34+ fraction containing the 
haematopoietic progenitors and at lower levels in the CD34- matures cell 
population.  
 The same pattern was found for PBX1, indicating that HPIP and PBX1 are co-
expressed in the same haematopoietic compartment. The sub cellular location 
shows that HPIP has a complex sub cellular distribution. It is largely bound to the 
cytoskeleton, but has the potential ability to shuttle between the nucleus and the 
cytoplasm by mechanisms involved in nuclear import and export signals.106 
Haematopoietic PBX-interacting protein (HPIP) interacts both with ERalpha and 
with ERbeta, and increases ERalpha target gene expression through activation of 
MAPK and AKT and enhanced ERalpha phosphorylation.107,108  
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2. Aims of the study 
 
  The aim of the present study was to characterize HPIPs´ function in normal 
and malignant haematopoietic stem cells. For this purpose we used the constitutive 
over expression techniques, using a MSCV based retroviral vector system, and all 
the classic human haematopoietic stem cell assays. The constitutive expression of 
HPIP was generated in human umbilical cord blood derived CD34+ Lin- population 
of stem cells. Complex in vitro assays that analyze various stages of differentiation 
of the haematopoietic lineages (primary and secondary CFC assays for the 
detection of clonogenic progenitors and analysis of their proliferative capacity, LTC-
IC assays for the detection of in vitro equivalents of HSC, MS5 assays for lymphoid 
development and megakaryocyte assays) as well as an in vivo models (NOD/SCID 
mouse model for the SRC frequency) were used to provide information about the 
function of HPIP in normal haematopoiesis. To characterize the relevant domains 
of HPIP, mutant forms of HPIP were generated and tested in the similar functional 
assays. Alterations in the transcriptome with constitutive expression of WT and 
mutant forms of HPIP were identified using cDNA micro array techniques. The 
cDNA micro array technique was used to identify and compare expression profiles 
of WT vs. mutant HPIP transduced hCB CD34+ Lin- cells. We also wanted to 
assess the role of potential collaborating genes with HPIP such as PBX1 and 
HOXB4, and by using double transduction experiments and then using the vectors 
stably expressing small hairpin RNA (siRNA) against the respective genes to 
knockdown their expression in K562 cell lines. The same experiments were 
performed on the primary CB cells to assess the affect of collaborating partners. In 
order to determine whether HPIP is differentially expressed in normal versus 
leukaemic cells or certain subtypes of leukaemia, expression of HPIP was 
analyzed in different molecularly and cytogenetically defined acute myeloid 
leukemias (AML) and acute lymphoblastic leukaemia (ALL) samples by using the 
cDNA micro array techniques. 
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3. Material and Methods 
 
3.1. Materials 
 
3.1.1. Buffers (All buffers were prepared in deionised water 
 
 3.1.1.1. Western Blot 
1? TBS (Tris-buffered saline) 1L 
4.84 g Tris base                                                                                         1X TBS 
1.60 g NaCl                  20 mM 
Tris-Cl 
80 ml Water.         136 mM NaCl 
HCl (6N) added till pH = 7.5 (final volume 1L) 
1x TBS-T (1L) 
100ml 10?TBS                                                        1X TBST 
900 ml water 
1 ml Tween 20 (stirring)               0.1% w/v 
Transfer buffer  
1? Transfer buffer (1L)                                                 1XTB 
100 ml 10? Transfer buffer                     25 mM Tris 
700 ml water          
192 mM Glycine 
200 ml methanol        20% methanol 
Ponceau Stain       
0.5 g Ponceau Stain               0.5% w/v  
1.0 ml glacial acetic acid                      
1%v/v 
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100 ml water 
Blocking Solution      
5 g skim milk powder                                                      5% 
w/v 
100 ml 1xTBS 
 
3.1.1.2. Agarose gel electrophoresis 
• TAE buffer        
Tris-HCl (pH 8.2)               40 mM  
Acetic Acid                20 
mM  
EDTA (pH 7.6)                            2 
mM  
 
3.1.1.3. Stem cell sorting buffers 
FACS buffer: (flow cytometry) 
Phosphate buffered saline (PBS)  
 FBS                      
3%  
 Propidium Iodide           1 mg/ml  
 
MACS buffer: (Magnetic associated cell sorting) 
PBS (pH 7.4)  
FBS                        
3%  
EDTA                               2 
mM  
 
3.1.2. Mediums 
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3.1.2.1. Serum free medium (SFM) 
IMDM (with L-glutamine) supplemented with the following:  
• BIT 9500 (BSA, insulin and transferrin) 20%  
• 2-Mercaptoethanol 10
-4 
M  
 
3.1.2.2. Haematopoietic cell washing medium  
IMDM supplemented with 2% FBS was used for washing of haematopoietic cells. 
The same buffer was used as a medium for injection of cells in mice. 
 
3.1.2.3. Lymphoid cell culture medium 
Lymphoid cell culture medium was prepared with RPMI supplemented with 5% AB 
human serum and 10% FBS.. 
 
3.1.2.4.  Maintenance/selection medium for  feeder cells 
Sl/Sl j-SF-tkneo j-IL-3-hytk cells 
• The DMEM medium supplemented with geneticin 418 (0.8mg/ml), hygromycin 
(0.125mg/ml) and 10% FBS. 
M2-10B4 j-GCSF-tkneo j-IL-3-hytk cells 
• The RPMI medium supplemented with geneticin 418(0.4mg/ml), hygromycin 
(0.06mg/ml) and 10%FBS. 
 
3.1.3. Mammalian cell lines  
 
• Phoenix Ampho: Packaging cell line is used for transient, episomal stable, 
and library generation for retroviral gene transfer experiments (Stanford 
University, Medical Centre, and USA).  
• PG13: PG13 is a mouse embryonic fibroblast used as a retroviral packaging 
cell line. It was purchased from ATCC. Introduction of retroviral vectors into PG13 
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cells results in the production of retrovirus virions capable of infecting cells from 
many species excluding mice.  
• K562: An erythroleukemia cell line derived from a chronic myeloid leukaemia 
patient in blast crisis. K562 cells were purchased from ATCC.  
• M2-10B4 j-GCSF-tkneo j-IL-3-hytk: Murine M2-10B4 fibroblasts engineered 
to produce high levels of both human granulocyte colony-stimulating factor (G-
CSF) and interleukin-3 (IL-3; 190 and 4 ng/mll, respectively), referred henceforth 
as M2-10B4 G-CSF / IL-3, were provided courteously provided by Connie Eaves 
(Terry Fox Laboratory, Vancouver, Canada).  
• Sl/Sl j-SF-tkneo j-IL-3-hytk: SI/SI fibroblasts engineered to produce high 
levels of soluble Steel factor (SF), with or without production of the 
transmembrane form of SF (60 and 4 ng/ ml, respectively), referred henceforth as 
Sl/Sl SF / IL-3, were provided kindly by Connie Eaves (Terry Fox Laboratory, 
Vancouver, Canada).  
• MS-5: Mouse stromal cells established by irradiation of the adherent cells in 
long-term bone marrow cultures derived from C3H/HeNSlc strain mice. 
 
3.1.4. The NOD-SCID Mice 
 
  The NOD/LtSz-scid strain was generated by crossing the SCID mutation from 
C.B-17- SCID mice onto the NOD background. C.B-17-scid mice lack functional T 
& B lymphocytes. The NOD strain mouse is an animal model of spontaneous 
autoimmune T-cell mediated insulin dependent diabetes mellitus (IDDM); 
however they have multiple defects in innate immunity. They are deficient in NK 
cell activity; display defects in myeloid development and function, and cannot 
generate either the classical or alternative pathways of haemolytic complement 
activation.  
 The NOD/LtSz-scid lacks an adaptive immune system; due to the absence of 
T cells, they do not develop autoimmune IDDM and remain insulitis- and diabetes 
free throughout life. However they carry the innate immune defects present in the 
parental NOD/Lt stock of mice.109 NOD/SCID mice were bred from the breeding 
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pairs originally obtained from Taconic Bomholt, Denmark and maintained in the 
animal facility located at the GSF-Haematology, Munich. All animals were 
handled under sterile conditions and maintained under micro isolators. xenografts 
into immunodeficient NOD-SCID mice are the gold standard readout for human 
long-term repopulating hematopoietic cells.110-112  
 
3.1.5. Mice related reagents and equipment 
 
Sterile Syringes: BD Plastipak 1 ml syringe (BD Biosciences, Palo Alto, CA) for 
injection of cells in mice and Kendall Monoject 3 ml syringes (Tyco Healthcare, UK) 
for bone marrow flushing and plating of CFC.  
Sterile needles: 0.5 x 25 mm for intra venous injection of cells in mice and 0.55 x 
25 mm (BD Microlance, Drogheda, Ireland) for bone marrow aspiration from living 
mice and flushing of bone marrow from extracted bones. 16 X 1.5 inch needles for 
dispensing and plating Methocult (CFC) media (Stem Cell Technologies, 
Vancouver, Canada).  
Ammonium Chloride solution: For erythrocyte lysis 0.8% NH4Cl with 0.1 mM 
EDTA(Stem Cell Technologies, Vancouver, Canada).  
Heparinized capillaries: (Microvette CB 300) plastic capillaries for collection of 
blood, containing 15 units (I.E) Lithium heparin per ml of blood (Sarstedt, 
Numbrecht, Germany).  
 
3.1.6. Bacterial strain 
 
• E. coli DH5á  
3.1.7. Cytokines and antibodies 
Cytokine Company 
SF Steel factor ImmunoTools Friesoythe; Germany 
GM-CSF Tebu-bio, Frankfurt, Germany 
G-CSF  Stem Cell Technologies 
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Flt-3-ligand PAN Biotech GmbH, Aidenbach, Germany 
IL6 Tebu-bio, Frankfurt, Germany 
IL3 ImmunoTools Friesoythe; Germany 
 
Antibody Antigen  (BD Pharmingen,Heidelberg, Germany) 
CD45PE Leukocyte common antigen 
CD34 PE Pluripotential haematopoietic stem cells 
CD38 APC Immune cell marker 
CD15PE Neutrophils and eosinophil antigen 
CD19 APC B-cell antigen 
CD33PE  Monocytic/myeloid lineage antigen 
CD36 APC Platelets, erythrocytes and monocytic antigen 
CD135 PE fms-like tyrosine kinase receptor-3 (Flt3) antigen 
CD71APC Adult erythropoietic cells  
CD41aAPC Platelets, late megakaryocytic antigen 
CD10APC Pre-B cells 
CD25APC activated B cells, some thymocytes, myeloid precursor 
antigen 
CD11bPE Leukocyte common antigen 
CD34APC Pluripotential haematopoietic stem cells 
CD133 Haematopoietic stem cell antigen 
CD117 Kit antigen 
Glyco A  Mature erythroid cells 
Isotype PE/APC Negative control 
 
 
3.1.8. Commercial kits  
 
• MACS CD34+ cell Isolation kits: CD34 and CD133 HSC were isolated from 
UCB using MACS kits from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany.  
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• GenElute™ HP Endotoxin-Free Plasmid Miniprep Kit: The kit was used for 
isolating plasmid DNA from recombinant E. coli cultures (3ml). It was purchased 
from    sigma Sigma-Aldrich, Taufkirchen, Germany. 
• GenElute™ HP Endotoxin-Free Plasmid Maxiprep Kit: The kit was used for 
isolating plasmid DNA from recombinant E. coli cultures (100ml). It was purchased 
from    sigma Sigma-Aldrich, Taufkirchen, Germany. 
• Qiaquick gel extraction kit: For gel extraction or cleanup of up to 10 ìg DNA 
(70 bp to 10 kb) from enzymatic reactions. DNA fragments purified with the 
QIAquick System are ready for direct use in all applications. The kit was purchased 
from Qiagen GmbH, Hilden, Germany. 
• QuickChange II XL site directed mutagenesis kit: The QuikChange XL 
system was used to make deletions in HPIP cDNA cloned in MSCV vector. The 
method was performed using PfuTurbo® DNA polymerase and a thermal 
temperature cycler. The kit was purchased from Agilant technologies, Germany 
• RNeasy mini kit: For purification of up to 100 ?g total RNA from cells, tissues, 
and yeast. The kit was purchased from Qiagen GmbH, Hilden, Germany. 
• DNeasy mini kit: Genomic DNA extraction kit from small cell numbers 
purchased from Qiagen GmbH, Hilden, Germany.  
• ThermoScriptTMRT PCR system: The ThermoScript RT-PCR System is 
designed for the sensitive and reproducible detection and analysis of RNA 
molecules in a two-step. ThermoScript. RT, an avian reverse transcriptase with 
reduced RNase H activity, is engineered to have higher thermal stability, produce 
higher yields of cDNA, and produce good amount of full-length cDNA transcripts. 
The kit was purchased from Invitrogen life technologies, Karlsruhe  
Germany. 
• Affymetrix GeneChip probe array: mRNA gene expression monitoring was 
done by using human genome U133 plus 2.0 Array array. The chips were bought 
from Affymetrix UK Ltd., UK. 
• Enzymes: T4 DNA ligase, Xho I, Eco RI, SacII and Hpa I, were purchased 
from New England Biolabs (NEB, Beverly, MA)  
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• DharmaFECT™ Transfection Reagents for siRNA Transfection: siRNA 
transfection in K562 was performed by using DarmaFECT reagents. The kit was 
purchased from Thermo scientific dharmacon siRNA tech., Bonn, Germany. 
• TaqMan® Express Plates: 96-well format complimenting customized line of 
individual TaqMan® Gene Expression Assays were used to confirm the microarray 
mRNA expressions.  
•  
• 3.1.9. Umbilical cord blood cells, plasmids and molecular markers 
•  
Biological Materials Company 
Peripheral blood (PB) 
AML patients  
Klinikum Grosshadern MEDIII, Frauen poliklinik 
Cord blood (CB) 
healthy donors 
Stem cell 
MSCV vector BCC, Vancouver, Canada 
Expression arrest TM 
pSM2 Retroviral 
shRNA  
Open Biosystems, Germany 
Standards markers, 
ladders 
Company 
1Kb Plus DNA ladder Invitrogen 
100 bp Dann  NEB, Frankfurt, Germany 
216 Kda Kaleidoscope 
Prestained  
protein ladder 
Bio-Rad, Germany 
260 Kda 
SpectraMulticolor  
protein ladder 
Fermentas, Germany 
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  3.1.10. Miscellenous reagents 
 
Reagents Company 
Acetic acid  Sigma-Aldrich, Taufkirchen, Germany 
Agar Sigma-Aldrich, Taufkirchen, Germany 
Agarose Sigma-Aldrich, Taufkirchen, Germany 
BIT Stem Cell Technologies, Vancouver, BC, Canada 
Bromphenolblue  Sigma-Aldrich, Taufkirchen, Germany 
BSA New England biotecnologies 
Calcium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Ciprobay 400 Bayer 
Chloroform Sigma-Aldrich, Taufkirchen, Germany 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
DMEM PAN Biotech, Aidenbach, Germany 
Ethanol Sigma-Aldrich, Taufkirchen, Germany 
Ethidium Bromide Sigma-Aldrich, Taufkirchen, Germany 
Fetal Bovine Serum PAN Biotech, Aidenbach, Germany 
Formaldehyde Sigma-Aldrich, Taufkirchen, Germany 
Geneticin GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
HEPES GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
Hydrocortisone 
(solucortef) 
Stem Cell Technologies, Vancouver, BC, Canada 
IMDM GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
Isopropanol Sigma-Aldrich, Taufkirchen, Germany 
LDL Stem Cell Technologies, Vancouver, BC, Canada 
L-Glutamine Sigma-Aldrich, Taufkirchen, Germany 
Methanol Sigma-Aldrich, Taufkirchen, Germany 
Milk powder Carl Roth Gmbh, Karlsruhe, Germany 
Methilcellulose H4434 Stem Cell Technologies, Vancouver, BC, Canada 
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Pancoll PAN Biotech, Aidenbach, Germany 
PBS PAN Biotech, Aidenbach, Germany 
Penicillin/Streptomycin GIBCO, Invitrogen Corporation, Karlsruhe, Germany  
RPMI PAN Biotech, Aidenbach, Germany 
SDS Sigma-Aldrich, Taufkirchen, Germany 
Sodium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Trypan blue GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
Trypsin/EDTA GIBCO, Invitrogen Corporation,Karlsruhe,Germany  
Â- Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
Cytofix (Cell fixation 
reagent) 
BD Pharmingen 
Hexadimethrine bromide Sigma-Aldrich, Taufkirchen, Germany 
 
 
  3.1.11. Software and machines 
 
Softwares Company 
CellQuest version 3.1f Becton Dickinson Immunocytometry Systems 
L calc  Stem Cell 
Microarray analysis Programm R Console (Bioconductor) 
Confocal Microscope Ziess 
SigmaPlot 6.0  SPSS Incorporated, Chicago, USA 
Adobe Illustrator  Adobe Systems, Unterschleißheim 
Adobe Photoshop  
 
Adobe Systems, Unterschleißheim  
Cellquest 3.3  
 
Beckton Dickinson, Heidelberg  
Microsoft Office 2003 Microsoft, Redmond, WA, USA  
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Machines Company 
FACS vantage Becton Dickinson FACScan  
FACS vantage Becton Dickinson FACSort flow cytometer 
Affymetrix Microarray  Fuidics Station, Affymetrix 
GeneChip Scanner 3000, Affymetrix 
AMAXA electroporation AMAXA GmBH 
 
 
 
3.1.12. Microscopes 
 
Axiovert 25 Inverted light microscope from Carl Zeiss, Germany, was used for 
normal visualization of cells in culture and for scoring colonies in CFC assays.  
Axiostar upright light microscope from Carl Zeiss, Germany, was used for cell 
counting and visualisation of cytospin preparations.  
 
3.2. Methods 
 
 3.2.1. Thawing, passage and freezing of mammalian cells 
 
 Umbilical cord blood (CB) was obtained from mothers undergoing cesarean 
delivery of normal, full-term infants and collected in heparin coated syringes. 
Approved institutional procedures were followed to obtain informed consent of the 
mothers. Frozen CD34+ cord blood or bone marrow (BM) cells from healthy donors 
were buying by (Cell Systems, St. Katharinen, Germany).  
Thawing: 10ml of warm culture medium (DMEM or IMDM with 10%FBS) was 
placed into a sterile 15mL tube. Frozen cells (-135 C or 80 C) cryotubes were 
thawed quickly in a water bath at 37°C with agitation. 2mL pipette was used to raw 
up the cell suspention and added very slowly and dropwise to the medium. The cell 
suspension was centrifuged at 1200rpm for 7 mins. The supernatant was decanted 
and the cell pellet obtained was resuspended in culture medium and placed into 
culture dishes or flasks. These were incubated at 37C in a CO2 incubator. A small 
aliquot of cells were taken apart for cell counting. For thawing UCB mononuclear 
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cells, DNase I was used (0.1 mg/ml) to prevent cell loss due to unwanted clumping 
of dead cells. 
Passage: When the cells in dishes or flasks obtained ~100% confluency they were 
split. Media was removed from the container. The cells were washed with PBS to 
free FBS traces. 1.5ml of (0.25%) Trypsin-EDTA was added. The container was 
placed in incubator at 37 c for 5-10 minutes. The adherent cells were checked in 
between if they were lifted from the surface of the dish. 1mL of culture medium with 
10%FBS was added to stop the enzymatic activity of trypsin. About 1/50 cell 
volume was transferred to a new 10 cm dish/flask (25cm2). The dish/flask was 
placed at the 37°C incubator with 5% CO2 in air and ?95% humidity. 
Freezing: confluent cells in 10 cm cell culture dishes were washed with warm PBS 
and trypsinized. Trypsinized cells were washed using their respective cell culture 
medium and pelleted down at 1200rpm for 7 mins. The pellet was resuspended in 
0.9 ml FBS. DMSO was added drop wise to the cells in FBS to a final 
concentration of 10%. Aliquots were transferred to cryotubes and stored in freezing 
containers at -80°C for 24 hours and transferred to liquid nitrogen for long term 
storage. 
 
 3.2.2. MSCV based retroviral vector 
 
  HPIP cDNA was cloned in pMSCV-IRES-YFP cassette in the Terry Fox 
Laboratory, Vancouver, Canada. This plasmid was provided to our lab for analysis 
of the role of  HPIP WT in human stem cells. As a control, the MSCV vector 
carrying only the IRES yellow fluorescent protein cassette was used.  
 
 3.2.3. Mutagenesis 
 
 The human gene HPIP was mutated at specific sites for structure-functional 
analysis of the HPIP WT protein. Mutagenesis was carried out using 
QuickChange® II XL site-directed mutagenesis kit (Stratagene). Specific primers 
were designed for desired deletion mutations. Two different regions were chosen 
for this purpose (1) Microtubule binding region (?MBR, 20aa deletion; position 
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spanning between 189-209) and (2) nuclear receptor and PBX interacting domain 
(?NRPID, deletion of  
 
Figure 3.2.3a: Stucture of HPIP protein with potential domains. HPIP is a 731 aa protein with 3 
PXXP motifs (shown in green), a microtubule binging region (shown in grey) and a nuclear receptor 
interacting domain (shown in red). 
 
 
Figure 3.2.3b: Deletion mutants of HPIP: The mutant form ?NRPID-HPIP-YFP has a set of 3 amino 
acids artificially deleted between position 615aa-619aa. This region has been implicated as a part of 
PBX binding domain105 (PBD position 560aa-633aa Abramovich et al, 2002) and also nuclear 
receptor interacting domain108 (N-terminal LXXLL motif position 615aa-619aa; Manavathi et al, 
2006). The second mutant ?MBR-HPIP-YFP has a deletion mutation in microtubule binding 
sequence (putative leucine repeat rich motif, LRR, position of motif spanning between 190aa-218aa; 
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LxxxLNxxLLxxLxLLxLxxLL), where a set of 24 amino acids was removed to disrupt the hydrophobic 
core of the HPIP WT protein 106(Abramovich et al, 2002). 
LXXLL motif/ PBX interacting domain, 3aa deletion; position spanning between 
615aa-619aa) of HPIP WT. The mutagenesis was performed according to the 
guidelines provided by the kit manufacturer. Different primers were ordered to 
specifically perform the in situ mutagenesis. Mutagenesis PCR was carried out with 
the QuickSolution™ Reagent provided in the kit, and the amplified Plasmid was 
transformed into XL10- Gold ultracompetent cells (included in the KIT). 
 Transformed bacteria were plated on agar plates and the plates were 
incubated at 37°C overnight. The next day early morning the plates were checked 
for healthy colonies. Selected colonies were picked and grown as mini cultures 
(minipreps, 3ml) in laura broth (prepared according to the directions on the bottle) 
overnight. The plasmid was extracted and purified using endotoxin free miniprep kit 
(Sigma) and sent for sequencing with YFP primers. Only the exact deletion mutant 
plasmids were chosen after sequence analysis and the remaining bacteria of the 
mini preps were used to culture a maxi prep (100ml). The final plasmids were 
purified using endotoxin free maxiprep kit (Sigma), measured and stored at -20°C. 
 
Table 3.2.3: Primers for mutagenesis 
 
 
  3.2.4. Generation of shRNA constructs 
 
  Small RNA sequences, using online database of cold spring harbour 
laboratories (www.cshl.org), were searched for generation of shRNA against HPIP 
mRNA. Five different small 19mer were selected from HPIP nucleotide sequence 
as small interfering RNA (siRNA) sequences. These sequences together with end 
HPIP WT mutant forms Primers for mutagenesis 
?MBR-HPIP-YFP 5´-TGCAGGCGGGGAGCTCCTCTTCTCAGG-3´frw 
5´- CCTGAGAAGAGGAGCTCCCCGCCTGCA-3´rev 
?NRPID-HPIP-YFP 5´- GTGCGGCAACAGGAGCTAAGAACATACTTGGC-3´frw 
5´- GCCAAGTATGTTCTTAGCTCCTGTTGCCGCAC-3´ rev 
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modifications (final nucleotide 22mer, table 2.2.3), and an integrated hairpin 
(19mer: TGTGAAGCCACAGATGTA) to finish it as small hairpin RNA (shRNA) 
were ordered at Metabion (Germany) for their manufacture. 
 
Table (3.2.4a): Final 22mer interfering nucleotide sequences against HPIP mRNA 
(www.cshl.org) 
 
siRNA name 
 
Sequence selected for cloning in mir30MSCV vector 
 
Si-HPIP-1 
 
5 ´-AGCGCCCTCAGTCTGGCAGCATTCC-3´ (start position 260) 
 
Si-HPIP-2 
 
5´-AGCGGGAGTGGAGTGGAAAGGAAAC-3´ (start position 1469) 
 
Si-HPIP-3 
 
5´-AGCGCTTCCACTCCTCTGGAGAAAC-3´ (start position 1700) 
 
Si-HPIP-4 
 
5´-AGAAGCCCTGCACTGATGTCACTTC-3´ (start position 2392) 
 
Si-HPIP-5 
 
5´-AGCGCCCTCTCTGCTAAGAACATAC-3´(start position 1905) 
 
 
 The LMP vector was purchased from Biocat technologies (Germany). These 
MSCV based retroviral (MSCV-mir30-GFP) vectors have been developed in the 
lab of Scott Lowe at CSHL to enable the efficient expression of shRNAmir 
constructs from the RNA Polymerase II (Pol II) promoters113 (Fig.3.2.4a). These 
vectors produce a highly efficient knockdown of the target protein even when 
present as a single copy. Other features of the vectors include: efficient and 
stable single copy knockdown, inducible expression with Tet-responsive 
promoters, easy cloning of shRNAmir from pSM2 vector into Pol II retroviral 
vectors and validation for in vitro and in vivo use. 
 
 shRNA design: To be able to generate the new shRNAmir clones, RNAi Central- 
RNAi oligo retriever (http://katahdin.cshl.org) was used. A typical shRNAmir is a 
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138 bp PCR product, which has a hairpin loop, the siRNA (22mer) and the flanking 
blunt  
 
 
Figure 3.2.4a: LMP microRNA-adapted Vector. The Vector map and sequence file has been 
compiled from published literature (Open Biosystems). This vector has not been completely 
sequenced. Unique restriction sites are shown. 
 
 
      (A) 
 
(B) 
Figure 3.2.4b: (A) shRNA construct. (B) A simple illustration of shRNA generation in a cell. 
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ends for ligation into the mir30 backbone of the digested LMP vector. Two different 
protocols were followed to generate the shRNA-HPIP pertaining to two different 
conditions to start with shRNA design. 
In the first condition we isolated the 22mer commercial sh-HPIP available at 
Biocat in a pSM2 vector (without GFP marker) and cloned it into LMP vector (with 
GFP marker)114 (Paddison et al 2004). In this case we performed a dual restriction 
digestion of the pSM2 sh-HPIP vector and the empty LMP vector with two 
enzymes (Xho1 and Ecor1) 
Reaction set up: 
• 1?l 10x Buffer (B) 
• 6.5?l H2O  
• 2?l DNA (0.3ìg/ìL) 
• 0.5?l per Enzyme  
b) The entire digest was run on a 1% agarose gel.  
c) The 138bp insert from the pSM2 vector and the LMP vector bands was gel 
isolated and purified using Qiaquick gel extraction kit (Qiagen). The cut insert and 
plasmid were eluted in 50ìl nuclease free water and quantified. 
d) To retrieve back the flanking ends of the sh-HPIP commercial hairpin, we 
performed a PCR using 5’ and 3’ miR30 primers (Table 2.2.3b), namely 
mir30_Xho1 frw and mir30-Ecor1 rev. the PCR amplified product (138 bp) was run 
on a 1% gel and isolated. 
d) Ligation was performed by using the sh-HPIPmir30 inserts and the LMP vector 
cut with EcoRI and XhoI (quantity taken in a ratio 1:3 respectively). 2?l of 10x 
ligase buffer and ligase enzyme (0.5?l) was used making a final reaction volume 
of 20?l. The ligation was performed for 3 hrs at room temperature. 
e) 2ìl of the diluted ligation mix was transformed into competent E.coli. The 
transformed cells were plated onto agar plates containing 100ìg/ml ampicillin.  
Plates were incubated at 30°C overnight.  
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In the second condition we ordered the complete shRNAmir30 (97 bp) 
constructs (Metabion, Germany). After a simple PCR we could insert the Xho1 
and Ecor1 flanking sites to the oligo. The final shRNAmir30 oligos contained the 
respective sh-HPIP (1, 2, 3, 4, 5; table 2.2.3a), a hairpin backbone and the 
flanking XhoI and EcorI blunt ends. We then continued with the restriction 
digestion step of the LMP vector and ligation of all the shRNAmir30 constructs as 
mentioned above.  
 
Table 3.2.4b: Common 5’ and 3’ miR30 primers ordered were as follows: 
 
Primer name 
 
Oligo  sequences 
 
mir30_Xho1 frw 
 
5-CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3´ 
 
mir30-Ecor1 rev 
 
5´-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA-3´ 
 
LMP_check 
 
5´-CCCTTGAACCTCCTCGTTCGACC-3´ 
 
 
Figure 3.2.4a 
 
Figure 2.2.3a: A typical 138bp shRNAmir30 nucleotide construct. A typical shRNAmir is a 
138 bp PCR product, which has a hairpin loop, the siRNA (22mer) and the flanking blunt ends 
with Xho1 and Ecor1 digestion sites. 
 
The LMP_check primer was also ordered to check the sequence (Sequiserve) 
of the final plasmids obtained. The knockdown of endogenous or overexpressed 
HPIP WT-YFP was tested on K562 cells at mRNA level using RT-PCR and at the 
protein level with the help of Western Blot. 
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  3.2.4. Establishment of stable PG13 packaging cell lines 
 
PG13 packaging cell lines were generated for different plasmids established 
for the current study as described before. These cell lines were used to perform 
infections on human umbilical cord blood CD34+ cells. PG13 cells are derived from 
TK-NIH/3T3 (mouse fibroblast) cells. The hybrid cell line is expressing a GALV 
envelope and the MoMLV virus core. The viruses produced have a wide host 
range (rat, hamster, cat, dog, monkey, bovine, human cells). Phoenix amphotropic 
cells were used for the transient transduction of PG13 with various viruses. Both 
these cell lines were cultured in DMEM with 10% fetal bovine serum and plated on 
corning dishes for transfections and transient transduction ( 2.5 x 106 cells per 10 
cm plate) a day prior to the experiment.  
  Transfection of Phoenix Ampho: Medium from Phoenix Ampho was 
changed 4 hours prior to transfection. In a 5 ml tube 20 ?g of plasmid DNA, 62.5 ml 
of 2M CaCl2 and dH2O to make up to 500 ml were mixed together. 500 ml of 2x 
HBS (ph=7) was added drop wise to form a precipitate. This mixture was added 
drop wise over the phoenix cells. After 12 hours of transfection, the medium was 
changed again over the Phoenix Ampho cells. The plates were left untouched for 
over 24 hrs for plasmid expression and virus collection in the medium.  
   Infection of PG13 cells: The virus containing medium (VCM) was collected  
after 24 hours, filtered through 0.45 ?m filter, supplemented with hexadimethrine 
bromide (polybrene, 5?g/ml) to give a final concentration of 0.5ng/ml. This VCM 
was added on PG13 packaging cells for viral infection. After repeated infections (3-
5 times), PG13 cells were left untouched for 48 hrs to allow the expression of YFP 
marker enclosed in the plasmid vector. The YFP expressing cells were sorted out 
using FACS and cultured for up to 2 weeks and resorted for the second time to 
acquire the most stably transduced PG13 cells. From these PG13 YFP+ cells, 
single cells were sorted into 96 well plates, expanded and viral production was 
titered on K562 cells. Individual PG13 YFP+ clones that produced the highest viral 
titre were identified and used for infecting umbilical cord blood CD34+ cells.  
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   The various plasmids used for transient transductions were: HPIP WT-YFP, 
?NRPID-HPIP-YFP, ?MBR-HPIP-YFP, sh-HPIP-GFP (1, 2, 3, 4, 5), YFP and GFP. 
 
3.2.6. Purification of umbilical cord blood CD34+ cells (CB CD34+) 
from mononuclear umbilical cord blood (UCB). 
 
 Umbilical cord blood was collected in heparinised syringes according to 
institutional guidelines following normal full-term deliveries. Informed consent was 
obtained in all cases. Mononuclear cells (MNC) were separated using density 
gradient centrifugation. Fresh umbilical cord blood, not older than 12 hours, was 
diluted with 2 volumes of PBS and layered over Pancoll. Usually 35 ml of diluted 
blood was layered over 15 ml Pancoll in a 50 ml conical tube. This was centrifuged 
at 400x g for 30 minutes at 20°C in a swinging-bucket rotor without brakes. The 
upper layer was aspirated and discarded, leaving the interphase undisturbed. The 
interphase containing MNC such as lymphocytes, monocytes and thrombocytes 
was then transferred to a new 50 ml tube, washed twice with large volumes of 
PBS, and then counted before labelling with magnetic bead or fluorochrome 
conjugated antibodies. 
 hCB CD34+ cell purification was conducted using MACS CD34+ Cell Isolation 
Kit that uses positive selection method. Cells were resuspended in a volume of 300 
ml per 1x108 MNCs These were blocked with 100 ml of FcR Blocking Reagent and 
labelled with 100 ml of CD34 Microbeads. When working with higher cell number, 
all the reagent volumes & the total volume was scaled up accordingly. This was 
followed by incubation for 30 minutes at 4-8°C. Cells were then washed twice by 
adding 10x the labelling volume of buffer and centrifuged at 300 x g for 15 minutes. 
The resultant cell pellet was then resuspended in 500 ml of MACS buffer and 
loaded into MS Column mounted on magnetic separator. The negative cells were 
allowed to pass through and the column was washed at least three times with 2 ml 
buffer.  
 The column was then removed from the separator, placed on a collection tube, 
loaded with fresh buffer, and the magnetically labelled cells flushed out using the 
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plunger. The magnetic separation was usually repeated to get a purity of more than 
95%. Purified cells were then frozen in FBS with 10% DMSO and thawed when 
needed for pre-stimulation and transduction. hCB CD34+ cell enrichment was done 
by FACS. For separation by FACS, MNCs were thawed from frozen stocks or 
prepared freshly from UCB and labelled using anti CD34-PE antibody (100 ml per 
108 cells), for 30 minutes on ice. Labelled cells were then washed twice with PBS, 
resuspended in FACS buffer and sorted.  The sorted cells with purity above 95 % 
were used for 48 hour pre-stimulation followed by transduction. 
 
  3.2.7. Feeders and Co-cultures 
 
  For the general feeder dependent long term culture initiating cell (LTC-ICs) 
assays, a mixture of M2-10B4-J-GCSF-tkneo-J-IL3-hytk (M2-10B4) fibroblasts and 
SL/SL-J-SF-tkneo-J-IL3-hytk (SL/SL) fibroblasts were used. M2-10B4 cells are a 
cloned line of mouse bone marrow originally engineered to produce G-CSF and IL-
3 (190 and 4 ng /ml respectively) and the SL/SL fibroblasts are a cell line originally 
established from SL/SL mouse embryos engineered to produce high levels of 
soluble Steel factor with or without production of the transmembrane form of SF 
(60 and 4 ng / ml respectively). The M2-10B and the SL/ SLcells were maintained 
by plating at a concentration of 1-2 x105 cells per 10 cm tissue culture dish 
(Corning) in RPMI, 10 % FCS, 0,4 mg/ml G418 and 0,06 mg/ml hygromicin and 
DMEM, 15 % FCS, 0,8 mg/ml G418 and 0,125 mg/ml hygromicin respectively.  
  Both murine feeders were irradiated with 8000 Rads (80 Gy) before being 
cocultured with CB CD34+ cells. Corning dishes (35 mm tissue culture) were pre-
coated with collagen solution (StemCell Technologies) to form a film that helps in 
the adherence of fibroblast cell lines. Both cell lines were mixed in a 1:1 ratio 
before plating on the dishes for LTC-IC assays. 
 
3.2.8. Transduction of CB CD34+ stem cell population  
 
 Specific PG13 cell lines were split into a couple of dishes to generate 
maximum possible VCM for the entire experiment. Enriched CB CD34+ cells were 
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thawed and counted. 1.5-2 ?106/ml cells were pre-stimulated for 48 hours in 
Iscoves modified Dulbecco medium (IMDM) containing a serum substitute 
BIT.(Stem Cell Technologies), 104M mercaptoethanol (Sigma), and supplemented 
with the following recombinant human cytokines: 100 ng/ml Flt-3 ligand, 100 ng/ml 
Steel factor, 20 ng/ml interleukin-3, 20 ng/ml IL-6, and 20 ng/ml granulocyte 
colony-stimulating factor (G-CSF). Corning dishes were coated with the 2ml of 
filtered VCM harvested from PG13 cells (the step was repeated at a difference of 
one hour  
 After 48 hours in culture, hCB CD34+ cells were harvested and resuspended in 
8ml of filtered virus-containing medium (VCM) supplemented with the same 
cytokines combination as mentioned above and hexadimethrine bromide 
(polybrene, 5?g/ml). This cell suspension was dispensed in the coated corning 
dishes that were prepared before. This procedure was repeated on the next two 
consecutive days for a total of 3 infections. At the end of third day, cells were 
harvested and transfered into fresh suspension dishes with serum-free medium 
supplemented with the same cytokine cocktail as above. These were incubated for 
an additional 48 hours prior to establishment of any in vitro assays.  
 For in vitro assays the cells were harvested and stained with PE-labelled anti-
CD34 antibody (Becton Dickinson, San Jose, CA) and isolation of the YFP+/GFP+/ 
CD34+ cells on a FACS Vantage (Becton Dickinson) sorter was performed. 
However, for in vivo studies, transduced cells were injected into non obese 
diabetic/severe combined immunodeficiency (NOD/SCID) mice directly after the 
third day of transduction (< 6 hours after the last exposure to fresh VCM) without 
any pre-selection of YFP expressing cells. In certain experiments some extra 
irradiated CB mononuclear cells were also used as carrier cells for injections. An 
aliquot was kept in vitro for further for the determination of the proportion of 
transduced cells to be injected into mice while performing limiting dilution 
experiments in mice.  
  In another setup of experiments we performed the double transductions on CB 
CD34+ cells. These were performed by collecting the VCM from two different PG13 
packaging cell lines, producing viruses’ containing 2 different plasmids. In this case 
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it was HPIP WT-YFP and HOXB4-GFP. The VCMs were mixed in a ratio of 1:1 
before coating it on the corning dishes. The cells were centrifuged at 600-700rpm 
for 20 minutes to facilitate the co-localization of different viruses on CB CD34+ 
cells. The cells were resuspended in dual VCM with polybrene for transduction to 
take place. 
  3.2.9. Detection of gene and protein expression 
 
  For amplification of HPIP WT cDNA (PCR) following primers were used: 
forward- 5´- CAGAGTCTGAGACTGGGCC -3´, reverse-5´- 
GCTGCAGCTCTGACTCCA-3´ and a human beta-actin mRNA was used as 
control, forward: 5´-CTTCAACACCCCCAGCCAT and reverse: 5´- 
TAATGTCACGCACGATTTCC-3´. These primers were used also to detect the 
presence of cDNA expression of all the mutant forms of HPIP WT in the PG13 
cells. The two step RT-PCR was performed to check the cDNA expression.  
 The ThermoScript RT-PCR system (Invitrogen) was used for the same. Protein 
expression of the HPIP WT and the mutant forms was documented using standard 
Western blotting. All the HPIP constructs are Flag tagged. Furthermore, two 
different monoclonal HPIP antibody specific for HPIP protein were designed and 
raised at the monoclonal peptide core facility (Dr E Kremmer), Hematologikum 
together with the Peptide Speciality Laboratories GmbH, Heidelberg.  These 
antibodies were used to test endogenous and retrovirally driven HPIP WT protein 
levels.  
  Total cellular protein was extracted from PG13-HPIP WT-YFP, PG13-ÄNRPID-
HPIP-YFP and PG13-?MBR-HPIP-YFP packaging cell lines by using RIPA lysis 
buffer. Whole cell lysates were run and separated on 10 % SDS-page gel and 
transferred to nitrocellulose membrane. Membranes were probed with an anti-
FLAG (Sigma) and anti-HPIP monoclonal antibody (Dr. Kremmer). The membrane 
was re-stained with secondary goat anti-mouse immunoglobulin for Flag tagged 
HPIP WT and with anti-goat secondary antibody for detection of endogenous 
expression of HPIP. Proteins were visualized using an ECL plus kit, according to 
manufacturer’s recommendations.  
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 The K562 cell line was transduced with different shRNAs generated against 
HPIP mRNA. These cells were double transduced with the HPIP-YFP virus and the  
 
Figure 3.2.8: A schematic representation of transduction experiment and all the following 
functional assays that are performed on primary human stem cells. 
 
shRNA virus to use this model for testing the efficacy of the different shRNAs. The 
protein was extracted and detected as mentioned above to estimate the 
downregulation of the HPIP protein and choose the best working shRNA against 
HPIP WT. 
 
3.2.10. Sub cellular localization of constitutively expressed 
HPPWT and its mutant forms. 
 
  For sub cellular localization studies, NIH3T3 and PG13 mouse fibroblasts were 
grown on coverslips and transfected with Flag tagged HPIP WT-YFP, ?NRPID-HPIP-
YFP and ?MBR-HPIP-YFP. After 24 hrs, cells were fixed with phosphate-buffered 
saline (PBS), 2% paraformaldehyde for 10 min, permeabilized with PBS 0.1% Triton X 
for 10 min and blocked with PBS 10% fetal calf serum (FCS) for 1 hr. Coverslips were 
incubated with monoclonal mouse Flag antibody (Sigma). Following extensive washing 
with PBS 0.1% Tween, Alexa 555 and Alexa 488-conjugated secondary antibodies 
were added for 1 hr. After further washing steps, cells were stained with DAPI and 
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mounted using Cytomat medium (DAKO, Glostrup, Denmark). Finally, immunostained 
species were analysed in a confocal fluorescence laser scanning system (TCS-SP2 
scanning system and DM IRB inverted microscope, Leica, Solms, Germany). 
 
 3.2.11. Colony forming cell assay 
# 
Haematopoietic colony-forming cells (CFC) were assayed using 
methylcellulose-based medium (MethoCult H 4434) (fig. 3.2.11). Required 
number of pre-aliquoted tubes of MethoCult medium was thawed overnight under 
refrigeration (2-8°C) or at room temperature. The cells were diluted with IMDM + 
2% FBS to 10X the final concentration(s) required for plating. For a duplicate 
assay 0.3 ml of diluted cells was added to 3 ml MethoCult tube and the contents 
vortexed vigorously. After about 5 minutes, 1.1 ml of cell: methylcellulose mixture 
was dispensed into 35 mm culture dishes using sterile a 3 ml syringe and16-
gauge bunt-end needle. The 35 mm culture dishes were placed into 10 cm petri 
dish along with an extra 35 mm dish containing sterile water to maintain humidity 
and placed in a CO2 incubator at 37°C and >95% humidity.  
CFC numbers were evaluated after an incubation period of 12-14 days and 
distinguished into following classes: Colony-forming unit-erythroid (CFU-E): 
Produces 1-2 cell clusters containing a total of 8-200 erythroblasts. A CFU-E 
consists of mature erythroid progenitors that require erythropoietin (EPO) for 
differentiation. Burst-forming unit-erythroid (BFU-E): Produces a colony 
containing >200 erythroblasts in a single or multiple clusters. A BFU-E consists of 
more immature progenitors than CFU-E and requires EPO and cytokines with 
burst-promoting activity such as Interleukin-3 (IL-3) and Stem Cell Factor (SCF) 
for optimal colony growth.  
Colony-forming unit-granulocyte, macrophage (CFU-GM): Produces a colony 
containing at least 20 granulocyte cells (CFU-G), macrophages (CFU-M) or cells 
of both lineages (CFU-GM). CFU-GM colonies arising from primitive progenitors 
may contain thousands of cells in single or multiple clusters. Colony-forming unit-
granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM): A multi-
Materials and Methods 
 54 
 
 
potential progenitor that produces a colony containing erythroblasts and cells of 
at  
FACS sorted YFP+ CD34+ cells + MH4434 
 
 
Cells added to MH4434 and vortexed.  
 
 
Cells dispensed into pre-tested petridishes using syringe and 
blunt-endneedle. 
 
Incubated for 14-16 days in humidified incubator at 37°C  
 
 
 
Figure 3.2.11: Human haematopoietic CFC assay in methylcellulose media detects haematopoietic 
progenitors (Figure adapted from the Stem Cell Technologies Catalogue). 
 
least two other recognizable lineages. Due to their primitive nature, CFU-GEMM 
tend to produce large colonies of >500 cells. 
3.2.12. Liquid expansion culture 
 
 For in vitro liquid expansion assays, transduced cord blood CD34+HPIP WT-
YFP+ ,CD34+ ?NRPID-HPIP-YFP+ and CD34+ ?MBR-HPIP-YFP+ cells were placed 
in cytokine-supplemented serum-free medium containing 10-4 M ß-
Mercaptoethanol, (Gibco) 20 % BIT (StemCell). For cord blood transduced cells 
100 ng/ml each of Flt-3 ligand and SF and 20ng/ml each of IL-3, IL-6 and G-CSF 
cytokines was added in the culture medium. Half-media change was performed 
every week and morphology of cells present in cultures at various time points was 
determined by performing cytospins. For cytospins 1x105 cells were fixed on a slide 
and stained with Wright-Giemsa. Every week 1x104 cells were plated in CFC assay 
after half-media change. In addition, separate aliquots were taken and incubated 
for 30 minutes on ice with a mouse isotype-matched control antibody (Becton 
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Dickinson) and large antibody panel against human antigens and analyzed by 
FACS for the expression of different lineages. 
 
3.2.13. B-lymphoid progenitor cell assay 
 
To test the influence of HPIP on B-cell development, two culture conditions 
were chosen (L. Coulombel, personal communication). Cells were cultured on 
murine MS-5 stromal cells in RPMI 1640 with 10% FCS and 5% human AB 
serum with either a combination of 3 growth factors as SCF (50ng/mL), IL-2 
(10ng/mL) and IL-15 (10ng/mL), to allow the development of predominantly B-
cells, or a combination of 6 growth factors (SCF (50ng/mL), IL-2 (10ng/mL) and 
IL-15 (10ng/mL), IL-7 (10ng/mL), Flt-3 L (100ng/mL) and TPO (50ng/mL) to allow 
the development of B-, NK cells and granulocytes / macrophages. After 4 weeks 
adherent and non-adherent cells were collected and analysed by FACS for the 
expression of CD34, CD38, myeloid (CD15, CD33), lymphoid  (CD19, CD10), 
erythroid (Glyco A, CD71) and megakaryocytic (CD41) cell surface markers. 
 
3.2.14. Human bulk long term culture initiating cell assay (Bulk 
LTC-IC). 
 
 M2-10B4 G-CSF / IL-3 and Sl/Sl SF / IL-3 cells (1:1 mixture) were established 
in 24-well flat-bottom culture plates at a density of 2 x105 cells per dish. On the day 
of assay, medium was removed from the wells. The test cells were added to the 
wells in 2ml of medium with cortisol (solucortef). The number of cells seeded per 
well were 5000. LTC-IC cultures were incubated at 37°C in humidified incubator 
(>95%) with 5 % CO2 in air for six weeks. For weekly half media changes, one half 
of the medium was removed and replaced with fresh LTC-IC medium each week 
for five weeks. To harvest the LTC-IC, all the adherent and non-adherent cells 
were removed from wells and place into individual 12x75 mm sterile tubes using a 
pipette and sterile tips. Single wells were harvested at a time to avoid cross 
contamination of samples. Wells were rinsed once with 1 ml PBS and added to 
tube. 1 ml Trypsin-EDTA was added to each well and incubated for 3 to 5 minutes 
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and examined for detached cells. Once the adherent cells are detached, the wells 
are washed with more PBS and the medium collected in the appropriated tube.  
 The wells are finally washed with 1 ml IMDM containing 2 % FBS and 
transferred to the specific tube. The tubes were centrifuged at 1200 rpm for 10 
minutes and the supernatant was removed without disturbing the cell pellet. 
Approximately 200ìL of medium was left along with the cell pellet and vortexed. To 
this 3ml of Methocult (H4434) methylcellulose medium was added and vortexed 
again. Each tube (contents of one well) was plated individually into 2 different (1.5 
ml/dish) 35 mm petri dish with 1 ml syringe (without needles attached). Different 
dishes (6-8) were placed in a 15 cm petri-dish along with an additional 60 mm open 
dish containing 5 ml sterile water to maintain humidity. The dishes are incubated at 
37°C in humidified incubator (>95 %) with 5% CO2 in air for 16-20 days. Colonies 
were scored as positive if one or more BFU-E, CFU-GM or CFU-GEMM were 
detected or scored as negative if no colonies were present.  
 The number of LTC-IC for the test cell population was calculated by dividing 
the total number of CFC detected in the culture by the average number of 
clonogenic progenitors per LTC-IC for the standard conditions used. Alternatively 
the values were expressed as LTC-IC derived CFC per number of test cells.115 
 
3.2.15. Fluorescence associated cell sorting 
 
 To determine the gene transfer efficiencies of cultured CD34+ cord blood cells 
after transduction, aliquots of cells were stained with anti-human CD34-PE 
antibody, washed twice with PBS and stained with propidium iodide 2?g/mL to 
exclude non-viable cells. Cells were analyzed using a FACS Calibure (Becton 
Dickinson) with Cellquest software (Macintosh, Cupertino,CA). 20.000 events were 
acquired to determine the proportion of positive cells present; positive cells were 
defined as those exhibiting a level of fluorescence exceeding 99.98% of that 
obtained with isotype-control antibodies labelled with the same fluorochromes. 
Green fluorescent protein (GFP) positive cells were detected by their increased 
fluorescence intensity within the fluorescence 1 channel. The percent gene transfer 
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efficiencies were calculated by the number of YFP+/GFP+CD34+ cells relative to the 
total number of CD34+ cells.  
 
3.2.16. Xenotransplantation models 
 
 NOD/LtSz-scid/scid (NOD/SCID) mice were bred and maintained in the animal 
facility of the Helmholtz- zentrum (Haematologikum) in microisolator cages 
containing autoclaved food and water. For competitive repopulating unit assay 
(CRU) in NOD/SCID mice, the mice were ordered from Taconic Farms, Bomholt, 
Denmark. Eight to nine weeks old NOD/SCID mice were sublethally irradiated with 
250 cGy from a 137Cs source an evening prior to injection. For transplantation, 
transduced cells were washed, counted, resuspended in PBS and injected into the 
lateral tail vein of irradiated mice (300-350?L/mouse).  After 6-8 weeks mice were 
sacrificed by CO2 inhalation (Fig 3.2.16). The cells from both tibiae and femurs of 
each mouse were collected for additional analyses.  
 The absolute number of cells in the marrow of each mouse was calculated 
assuming that the contents of both femurs and both tibiae represent 25% of the 
total marrowFor the bulk cell experiments, a certain fixed amount of cells were 
used to inject in mice and engraftment level, differentiation and proliferation levels 
in vivo were estimated 6-8 weeks post transplantations. However, in limiting 
dilution assays carried out in mice, different numbers of cell dilutions were 
generated and cohorts of mice were injected with different number of test cells. 
After BM harvest the frequency of competitive repopulating unit (CRU) or Scid 
repopulating cells (SRC) was assessed using L calc software (stem cells) 
 
3.2.16. Analysis of the BM of sacrificed mice. 
 
 Cells harvested from bone marrow of NOD/SCID mice were resuspended in 7 
% ammonium chloride (Stem Cell Technology, Vancouver, Canada) and placed on 
ice for 20-30 minutes for lyses of red blood cells. After this, cells were washed and 
re-suspended in Hanks balanced salt solution (Stem Cell Technologies, 
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Vancouver, Canada). Cells were washed and stained with anti-human CD45-PE 
(Becton Dickinson).  
 
 
Figure 3.2.16: A schematic presentation of in vivo experiment set in laboratory. The 
transduced cells are injected in the tail of mice without any YFP expression pre-selection. After 6-8 
weeks of transplantation the surviving mice are sacrificed and the BM is harvested for engraftment 
of human CB cells and levels of YFP+ expression in these mice. 
 
 A proportion of the cells were incubated 30 minutes on ice with a mouse IgG1 
isotype control (Becton Dickinson Immunocytometry Systems, San Jose, CA) to 
evaluate non-specific immunofluorescence. The remaining cells were incubated 
with fluoresceinated anti-CD45 a human-specific pan-leukocyte marker to detect 
human cells. The percentage of human CBCD45+ cells was determined after 
excluding 99.9 % of nonviable (propidium iodide) cells and at least 99.9 % of cells 
labelled with isotype control antibodies. To determine lineage differentiation and 
multilineage engraftment, cells were stained for 30 minutes at 4°C, with the 
antihuman CD45-PE phycoerythrin (PE;Becton Dickinson) and antihuman CD71-
APC antibodies (OKT9) to quantify the total number of human cells present 
(CD45+/71+), with antihuman CD34 8G12-Cy5 and antihuman CD19-PE to quantify 
the number of human B cells present, and with antihuman CD15-PE (Becton 
Dickinson) to quantify the number of human myeloid cells present.  
 Additional antibodies used for the detection of erythroid positive cells fraction 
were the antihuman GlyA-PE and antihuman CD36-APC (Becton Dickinson), and 
antihuman CD38- PE (Becton Dickinson). Expression of basophiles was detected 
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using CD25-APC (IL-2Rá), antihuman CD40-APC and Cd11b-PE and antihuman 
CD41a-PE (Becton Dickinson). Multilineage engraftment was considered if there 
were >5 CD34+CD19+ human cells and > 5 CD45+CD15+ human cells per 2x104 
viable cells analyzed.116 
 
3.2.17. Generation of monoclonal antibody against HPIP WT 
 
In cooperation with Dr. E Kremmer (GSF, München) and Dr. HR Rackwitz (PSL 
GmbH, Heidelberg) two HPIP peptides, namely HP1 (PQSGSILTEETV) and HP2 
(KQKQPRWREGTKD) were synthesized and used to immunize rats. Antibody-
secreting hybridoma cells were produced by fusing the spleen cells from the 
immunized rats with myeloma cells. Successfully fused cells were propagated in 
selective medium and screened for antibody production. Using ELISA and western 
blot productive hybridoma clones were identified to specifically detect the protein. 
Productive hybridoma clones were expanded and cloned to establish monoclonal 
hybridoma cell lines. Supernatants of these cell lines were used for western blots 
and immunoprecipitations. 
 
3.2.18. Affymetrix Genechip expression analysis 
 
Fresh RNA was prepared using RNA easy micro kit using ? 2X105 retrovirally 
transduced Cord blood CD34+ cells from each arm. Biotinylated target from these 
purified RNA samples suitable for hybridization to gene chip expression probe 
arrays was performed using a Two-Cycle target labelling and control KIT. 
 
3.3. Analysis 
 
3.3.1. Statistics 
Data were statistically tested using Student’s t-test (Microsoft Excel). Differences with p-
values ?0.05 were considered statistically significant. Statistical analysis for calculating 
CRU frequency was performed using L-Calc™ software for limiting dilution assays. 
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3.3.2. Gene expression profile 
 
Differential expressions of RNA in this over expression model were performed using R 
program, Tinn R program.  
 
3.3.3 Confocal Microscope 
 
Expression of proteins in cells was examined using an anti-flag antibody. The photos from 
different channels were acquired using Leica Confocal Software.  
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4. Results 
 
4.1. Transduction efficiency measured on the CD34+ progenitor pool of 
umbilical cord blood cells (hUCB derived CD34+Lin- cells). 
 
Human primary umbilical cord blood cells (hUCB derived CD34+Lin-) were 
purchased from Stem Cell Technologies. The hCB CD34+ stem cell pool was 
retroviral transfected with bi-cistronic vectors containing either WT or HPIP mutant 
cDNA or a yellow fluorescent protein (YFP) as a reporter gene (see methods, 
p.48). The analogous vector containing YFP only was used as a control. The gene 
delivery efficiencies were determined by measuring the proportion of cells 
expressing the YFP, with the help of the FACS Calibur. The mean transduction 
efficiency of the double positive cells (CD34+YFP+) was 9.55% (±5.92%) for HPIP 
WT-YFP+ and 11.14% (±6.23%) for YFP+ cells respectively, in hCB CD34+ cells 
relative to the total number of the input hCB CD34+ cell population (n=13).  
The mean transduction efficiency was 9.11% (±2.02%) for CD34+?NRPID-
HPIP-YFP+ cells (n=6) and 7.1% (±0.15%) for CD34+?MBR-HPIP-YFP+ cells (n=6, 
Fig. 4.1), relative to the total input hCB CD34+ cell population. There were no 
significant differences observed between the mean transduction efficiencies of all 
the vectors in human hCB CD34+ cells.  
 
  4.2. RNA and protein expression analysis  
 
  The complete cDNA of HPIP WT was cloned into the bi-cistronic vector 
enclosing an IRES-YFP cassette based on the murine stem cell virus (MSCV) 
backbone (HPIP virus). Mutagenesis of MSCV-HPIP WT-IRES-YFP was 
performed to create the two mutants of HPIP WT namely ?NRPID-HPIP-YFP and 
?MBR-HPIP-YFP (see methods, p-39). In parallel MSCV–IRES–YFP vector was 
used as a control. High titre virus producing cell lines were generated from the 
GALV pseudo-typed PG13 packaging cell line in case of all the four constructs. 
K562 cell lines were retro-virally transduced and the full-length provirus integration 
and expression  
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YFP
+
 cells    
 
Figure 4.1: Acquisition plots representing retroviral transduction efficiency in hUCB CD34
+ 
Lin
-
 cells. hCB CD34+ cells were retroviral transduced with HPIP WT (dot plot above left), ?NRPID-
HPIP-YFP (dot plot above right), ?MBR-HPIP-YFP (dot plot below left) and YFP (dot plot below 
right). The cells were stained with CD34 PE cell surface marker, washed with PBS and treated with 
medium containing Propidium Iodide (FACS buffer, see methods, p-30) and analysed with the help 
of the FACS Calibur. Each dot plot represents four different compartments of the cells. These are 
four different kinds of enriched populations shown in four different sections in each plot; (please 
refer to a single plot presented above) hCD34+ only (upper left), hCD34+YFP+ (upper right), hCD34-
YFP+ (lower right) and hCD34-YFP- (lower right) The population that was sorted further for the 
experiment in each case is marked with the green box (hCD34+YFP+), showing the % positive 
CD34+YFP+ cells. These double positive cells were sorted and used further for in vitro and in vivo 
assays. 
 
Figure 4.2a: cDNA expression analysis using RT-PCR in K562 cell line. K562 cells were 
transduced with WT and HPIP mutant forms and YFP control viruses. RNA was extracted from 
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stable K562 cell lines and the cDNA was generated by performing RT-PCR, using primers specific 
for HPIP WT, frw: 5´-CAGAGTCTGAGACTGGGCC-3´ and reverse- 5´- 
GCTGCAGCTCTGACTCCA-3´ primers were able to amplify all the constitutively expressed WT and 
mutant HPIP cDNA (see methods, p-50). (A) Constitutively expressed HPIP WT-YFP, (B) 
constitutively expressed ?NRPID-HPIP-YFP, (C) constitutively expressed ?MBR-HPIP-YFP, (D) 
endogenous HPIP expressed in K562-YFP cell line, (E) endogenous HPIP in K562 cell line.  
 
Figure 4.2b: Western blot of flag tagged proteins in stably transduced K562 cell lines. The 
above blots depict the presence of the WT and HPIP mutant form proteins in cell lysates from K562 
stably transduced cell lines. The lysates from PG13 and K562 were prepared using RIPA cell lysis 
buffer 2. The samples were run on a 7.5% SDS gel. In both above cases the HPIP-WT-YFP (105 
KD) and ?NRPID-HPIP-YFP (a little lower < 105 KD) expressing cells show strong protein 
expression. However the expression of ?MBR-HPIP-YFP was unpredictable. 
 
was confirmed by RT–PCR (Fig. 4.2a) and immunoprecipitation on western blot 
(Fig. 4.2b).  
  An approximate equal expression of all the constitutively overexpressed 
cDNAs could be verified with the help of RT-PCR. On the western blot, the flag 
tagged protein expression could be predicted for overexpressed/flag tagged HPIP 
WT and ?NRPID-HPIP-YFP proteins (the same has been demonstrated with an 
immunoprecipitation blot in figure 4.2b). Expressions could also be depicted with a 
monoclonal antibody generated specifically for the detection of endogenous HPIP 
WT protein for both the above mentioned HPIP forms. However, the protein 
expression of ?MBR-HPIP-YFP was low to unpredictable on western blot.  
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4.3. Subcellular localization of the constitutively expressed protein 
 
 Subcellular localization of WT and HPIP mutant forms was investigated with 
immunofluorescence staining at the single cell level. Protein expression at the cell 
level and protein localization was predicted using immunoassaying using the anti-
FLAG antibody staining. For microscopy, the cells were grown on 18x18 mm cover 
slips. After overnight staining with anti-flag, cells were washed with PBS and fixed 
for 10 min in 3.7% formaldehyde/PBS.  
 All the photos were taken on an automated Axiovert 200M microscope 
equipped with single band pass filter sets for visualization of DAPI (blue 
fluorescence), CFP (Red fluorescence) and YFP (Yellow fluorescence). Images 
were recorded and processed using open lab 3.08. Clearly, expression of proteins 
at the cell level and their cytoplasmic localization were detectable (Fig. 4.3) with the 
help of confocal microscopy. There were no visible differences observed in the 
fluorescence intensity of CFP (anti-FLAG) and YFP, suggesting the positive 
expression correlation of the test proteins and the control YFP.  The figure 4.3 
shows the presence of HPIP- WT-YFP, ?NRPID-HPIP-YFP and ?MBR-HPIP-YFP 
proteins in cytoplasm. There was no CFP signal detectable in the nucleus of the 
cells.  
 This confirms that WT and mutant forms are primarily located in cytoplasm of 
the cells. The deletion in both of these domains of HPIP could not render HPIP 
delocalized inside the cells. We could clearly see a signal of CFP tagged FLAG-
?MBR-HPIP (Fig 4.3-III), protein in this experiment, which was previously not 
detectable in the western blots. 
 
 4.4. In vitro proliferation assay of the human haematopoietic stem 
cell. 
 
 4.4.1. In vitro commitment and differentiation of transduced cells.  
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 Liquid expansion culture system for human haematopoietic progenitor cells has 
been developed to monitor the commitment and differentiation of hCD34+ cells to  
 
Figure 4.3: Immunostaining and confocal laser scanning of flag tagged WT and HPIP mutant form 
of proteins. HEK 293T cells were grown on cover slips. HPIP-WT and its mutant forms (?NRPID-
HPIP-YFP and ?MBR-HPIP-YFP) were transfected and expressed in HEK 293T cell lines. As a 
control MSCV-YFP construct was used. The cells were fixed with PSA and stained with DAPI (Blue 
in colour), YFP (Yellow in colour) and anti-FLAG (Red in colour). Pictures were captured using 
Axiovert 200M/confocal microscope. In the figures above you can observe (third photo on the right 
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hand side) the staining with anti-Flag alone that revealed the presence of : (I) HPIP WT-YFP 
expression, primarily in cytoplasm (Red) (II) ?NRPID-HPIP-YFP expression primarily in cytoplasm 
(Red) (III) ?MBR-HPIP-YFP expression primarily in cytoplasm (Red) and (IV) YFP only with 
negative results for anti-Flag staining. Confocal laser scanning demonstrates that HPIP-WT and its 
mutant form proteins are primarily localized in the cytoplasm.  
 
specific lineages and the maintenance and expansion of hCD34+ cells in vitro. As 
an initial test to determine whether HPIP-WT or its mutant forms would affect the 
commitment and differentiation capacity of human haematopoietic progenitor cells, 
a total of 1x104 highly purified (FACS) hCD34+HPIP WT-YFP+, hCD34+?NRPID-
HPIP-YFP+, hCD34+?MBR-HPIP-YFP+ and hCD34+YFP+ cells were cultured in 
serum free medium supplemented with cytokines for 5 weeks (see methods, p-53).  
 Constitutive expression of HPIP-WT and its mutant forms decreased the cell 
proliferation in vitro at every time point measured between week 2 to 4: at week 
two, HPIP transduced hCB CD34+ cells expanded from 10,000 cells plated at the 
beginning of the culture to 3.1x106 cells, for ?NRPID-HPIP transduced hCB CD34+ 
cells expanded to 8.7x105 cells and for ?MBR-HPIP transduced hCB CD34+ cells 
expanded to 1.27x106 cells as compared to 5.1x106 cells in control YFP. At week 
three HPIP transduced hCB CD34+ cells expanded to 4.19x106 ,  ?NRPID-HPIP 
transduced hCB CD34+ cells expanded to 1.4x106 and ?MBR-HPIP transduced 
hCB CD34+ cells expanded to 1.6x106 as compared to 6.03x106 cells in the control 
YFP. 
 The average cell expansion decreased between week 2 and week 4 for HPIP 
transduced hCB CD34+ cells by 39% and 30.5% respectively, for ?NRPID-HPIP 
transduced hCB CD34+ cells by 82% and 77.5% respectively (p?0.01) and for 
?MBR-HPIP transduced hCB CD34+ cells by 75% and 73.5 % (p?0.01) 
respectively, relative to the control YFP (n=3). The average fold change in the 
number of cells measured between week 2 and week 4 was 1.5 fold decrease in 
cell number (p?0.05) for cells expressing HPIP-WT, 4.1 fold decrease in cell 
number (p?0.01) for cells expressing ?NRPID-HPIP, and 3.5 fold decrease in cell 
number (p?0.01) for cells expressing ?MBR-HPIP as compared to control YFP 
expressing cells. 
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 In addition the frequency and absolute number of clonogenic progenitors was 
assessed on weekly intervals for a time period of 5 weeks in liquid expansion 
culture. During the half medium change of the liquid expansion culture one third of 
the total harvested cell number was plated in methylcellulose (Methocult-H4434) to  
 
Figure 4.4a: Proliferation of transduced cells in vitro. A total number of 10, 000 hCD34+ YFP+ 
cells were sorted after the retroviral transduction of WT and HPIP mutant forms in hCD34+ cells. 
These cells were suspended in cytokine-supplemented (Flt-3 ligand, SF, IL-3, IL-6 and G-CSF) 
serum-free medium (see methods, p-53). As demonstrated above, the expression of the mutant 
forms of HPIP showed a significant decrease in the number cell proliferation in suspension liquid 
culture between 3-4 weeks. There was a significant decrease of 3.5 fold in the proliferating cells in 
the case of ?MBR-HPIP-YFP (***p?0.01) and 4.1 in the case of ?NRPID-HPIP-YFP (***p?0.01, 
n=3) as compared to the control YFP (indicated with red line). 
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Figure 4.4b: Absolute number of clonogenic progenitors per dish in liquid expansion assay. 
The graph illustrates the absolute number of clonogenic progenitors per experimental group at the 
week 2 and week 4. Expression of HPIP-WT (p<0.01, n=3) was able to enhance significantly, the 
number of absolute progenitors per dish at week 2 relative to control YFP.  At week 4 we could still 
see a similar significant difference (p<0.05) in the number of absolute clonogenic progenitors, with 
an increase in the number of progenitors in the case of HPIP relative to the YFP control.  
 
evaluate the colony forming potential of the proliferating cells in the long term 
expansion culture in vitro. Due to very less number of proliferating cells in both the 
mutant forms of HPIP, we could not perform CFC assays from the liquid expansion 
cultures.  
 At week two, the average number of colonies for HPIP transduced hCB CD34+ 
cells was equal to 43.63 (±4.58) per 5x105 input cells (p?0.05, n=3)(harvested from 
the liquid expansion culture) as compared to control YFP with an average number 
of colonies equal to 26.8 (±2.6) per 5x105 cells (n=3). A 1.6 fold increase in the 
number of colonies generated by HPIP transduced hCB CD34+ cells (p?0.05, n=3) 
was observed at week 2 as compared to the colonies generated by the control YFP 
transduced hCB CD34+ cells. At week four, the average number of colonies for 
HPIP transduced hCB CD34+ cells was equal to 28.03 (±9.4) per 1.5x106 input 
cells (p?0.05) as compared to the control YFP with an average number of colonies 
equal to 11.2 (±6.7) per 1.5x106 input cells (n=3). A 2.5 fold increase in the number 
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of colonies generated by HPIP transduced hCB CD34+ cells (p?0.05, n=3) was 
observed at week 4 as compared to the colonies generated by the control YFP 
transduced hCB CD34+ cells.  
 Furthermore the absolute number of progenitors was calculated considering 
the number of colonies generated, for each experimental arm from the total 
number of cells at week 2 and 4. At week 2, the expression of HPIP-WT in hCB 
CD34+ cells produced 258.2 (±5) absolute numbers of progenitors, with a 
significant increase relative to the 27.28 (±3) numbers of absolute progenitors 
generated by control YFP. At week 4, HPIP-WT expression could induce 58.98 
(±9) number of absolute progenitors over 32.3 (±11) numbers of progenitor cells 
generated in the control YFP. 
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4.5. Colony forming cell (CFC) assays 
 
4.5.1. Quantification of committed haematopoietic progenitor cells 
in vitro  
 
 Colony-forming cell (CFC) assay, also referred to as the methylcellulose 
assay, is the commonly employed in vitro assay for the quantification of committed 
haematopoietic progenitors. Clonogenic haematopoietic assays detect progenitor 
cells committed to a specific lineage by seeding candidate populations into semi-
solid methylcellulose media. Progenitors identified by this assay are retrospectively 
classified as colony forming cells (CFC) and can be quantitatively subdivided into 
lineage restricted subtypes by examining the composition of the resulting progeny 
(methods, p-51)(Fig. 4.5.1a). 
 In order to test the impact of HPIP and its mutants on the growth of clonogenic 
progenitors, a total number of 3,300 hCB CD34+YFP+ cells transduced with WT 
and mutant forms (HPIP-WT-YFP, ?NRPID-HPIP-YFP, ?MBR-HPIP-YFP) and 
YFP control, were suspended in methylcellulose-H4434 (Methocult H4434) and 
plated into 2 methylcellulose dishes with an approximate number of 1000 
CD34+YFP+cells plated per dish. The colony formation was evaluated after 14 days 
of incubation at 37ºC. The HPIP transduced hCB CD34+ cells formed an average 
number of 112 (±9.2) colonies per 1000 hCB CD34+YFP+ initially plated cells, the 
?NRPID-HPIP-YFP transduced hCB CD34+ formed 97 (±9.3) colonies per 1000 
hCB CD34+YFP+ initially plated cells (p?0.05) and the ?MBR-HPIP-YFP 
transduced hCB CD34+ formed 102 (±4.2) colonies per 1000 hCB CD34+YFP+ 
initially plated cells (p?0.05)  relative to 80 (+11.2) colonies formed by the control 
YFP transduced cells (n=6; Fig 4.5.1b).  
 An increase in the number of erythroid colonies was observed in the case of 
HPIP transduced hCB CD34+ cells with an average number of 46.35 (±6.9) 
colonies per 1000 hCB CD34+YFP+ initially plated cells (p?0.01, n=6) and ?MBR-
HPIP-YFP transduced hCB CD34+ cells with an average number of 40.8 (±5.9) 
colonies generated per 1000 hCB CD34+YFP+ initially plated cells (p?0.01, n=6), as  
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Figure 4.5.1a: Images of colonies obtained from hCB CD34+ cells grown on Methocult H4434. 
An illustration of (a) Erythroid E ;  (b) Granulocytic G;  (c) Megakaryocytic M;  (d) Mixed GM and (e) 
Mixed GEMM colonies formed after plating human hCB CD34+ cells in Methocult H4434 and scored 
after 14 days of culture . The colonies are thoroughly analysed for their morphology and scored 
accordingly. The above pictures represent the colonies formed by normal human haematopoietic 
CD34+ cells 
 
Figure 4.5.1b: The Colony Forming Cell (CFC) Assay. The graph illustrates the number of 
colonies obtained for hCD34+YFP+ cells expressing  WT and HPIP mutant forms per 1000 cells 
plated initially per dish in Methocult H4434. The dishes were incubated for 14 days and thereafter 
colonies were scored and morphology was assessed. HPIP-WT increased the number of erythroid 
colonies (p ? 0.01, n = 6) and mutation in the Nuclear receptor and PBX1 binding domain (NRPID) 
nulls the effect. The microtubule binding region mutant (MBR) increases the formation of erythroid 
colonies (p ? 0.01, n = 6), similar to the effect produced by HPIP-WT as compared to control YFP 
(indicated by red lines). Both the mutant forms of HPIP increased the number of GEMM colonies (p 
? 0.01) as compared to the control YFP. 
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compared to an average of 25.4 (±3.5) colonies generated per 1000 hCB 
CD34+YFP+ initially plated cells, by control YFP transduced cells (n=6). ?NRPID-
HPIP-YFP transduced hCB CD34+ cells generated 25.3 (±7.1) colonies per 1000 
hCB CD34+YFP+ initially plated cells with no significant change observed as 
compared to the control YFP transduced cells (p=ns, n=6).  
 There was a slight increase observed in the primitive colony-forming unit-
granulocyte, erythroid, macrophage, megakaryocytic (GEMM colonies), in the case 
of HPIP transduced hCB CD34+ cells with an average of 18.1 (±2) colonies per 
1000 hCB CD34+YFP+ initially plated cells (p=ns, n=6). A significant increase was 
observed in the number of GEMM colonies in the case of ?NRPID-HPIP-YFP 
transduced hCB CD34+ cells with and average of 32.5 (±3.2) colonies generated 
per 1000 hCB CD34+YFP+ initially plated cells (p?0.0005, n=6) and ?MBR-HPIP-
YFP transduced hCB CD34+ cells with an average of 25.8 (±2.7) colonies 
generated per 1000 hCB CD34+YFP+ initially plated cells as compared with 10.9 
(±2.8) (p?0.003, n=6) colonies generated by control YFP transduced cells (p?0.01, 
n=6).   
  The absolute number of cells harvested per CFC assay did not show a 
significant change in the cell number generated by HPIP transduced hCB CD34+  
cells (3.4x106 ± 5.2x105 cells, p=ns), for ?NRPID-HPIP transduced hCB CD34+ 
cells (2.5x106 ± 4.6x105, p=ns) relative to the control YFP per 1000 hCB 
CD34+YFP+ initially plated cells (n=6). A significant decrease was observed in the 
absolute number of cells harvested per CFC assay (all the cells from one complete 
CFC dish ) for ?MBR-HPIP-YFP transduced hCB CD34+ cells (1.6x106 ± 5.2x105) 
(p?0.06, n=6) relative to the absolute number of cells in the case of control YFP per 
1000 hCB CD34+YFP+ initially plated cells.  
 Further we calculated the absolute number of cells harvested per colony from 
each CFC assay. The number of cells per colony did not show a significant change 
in the case of HPIP transduced hCB CD34+ cells (3.8x104 ± 5915 cells/ colony, 
p=ns), and for ?NRPID-HPIP transduced hCB CD34+ cells (2.6x104 ± 5615 cells/ 
colony, p=ns) relative to the control YFP transduced hCB CD34+ cells (4.2x104± 
1x104 cells/colony)(p=ns, n=6). In the case of ?MBR-HPIP transduced hCB CD34+ 
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cells, the absolute number of cells per colony showed a significant decrease 
equivalent to 1.5x104 ± 4510 cells/colony relative to control YFP (p?0.03, n=6).  
 Morphologically, ?NRPID-HPIP transduced hCB CD34+ cells generated 
smaller M and GEMM colonies as compared to HPIP transduced hCB CD34+ cells. 
Also ?MBR-HPIP transduced hCB CD34+ cells generated larger GEMM colonies 
as compared to HPIP transduced hCB CD34+ cells and YFP transduced hCB 
CD34+ cells.  The figure 4.5.1a illustrates the morphology of colonies that are 
obtained in CFC assay performed with hCD34+ cells. The figure 4.5.1b and figure 
4.5.1c illustrates graphically the primary CFC data from the assays. 
 
 4.5.3. CFC replating Assays  
 
 In order to quantify the self-renewal potential of clonogenic progenitors, 
secondary CFC assays were performed. The methylcellulose dishes containing 
primary colonies were harvested, and replated (1/4 cells generated per primary 
CFC assay plated per secondary CFC assay) into fresh methylcellulose dishes and 
scored after 14 days. The constitutive HPIP-WT expression in HPIP transduced 
hCB CD34+ cells decreased the number of secondary colonies with the generation 
of 27.75 (± 2.79) average number of secondary colonies per 1x106 cells harvested 
from the primary CFC assay, as compared to the control YFP transduced hCB 
CD34+ cells, with 34.9 (±7.9) generated colonies per 1x106 cells harvested from the 
primary CFC assay.  
 The constitutive expression of HPIP mutant forms ?NRPID-HPIP in hCB 
CD34+ cells generated a total number of (sum total of E, G, M, GM, GEMM) 30.8 
(±2.79) colonies per 1x106 cells harvested from the primary CFC assay and ?MBR-
HPIP in hCB CD34+ cells generated 36 (±6.1) colonies per 1X106 cells harvested 
from the primary CFC assay with no significant changes as compared to control 
YFP transduced hCB CD34+ cells (34.9 ±7.9) (p=ns, n=6)(Fig. 4.5.2a). replating of 
CFCs formed by ?NRPID-HPIP-YFP transduced hCB CD34+ cells showed a 
significant increase in the formation of granulocytic colonies with an absolute 
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number of 14 (+3.41) colonies per 1X106 cells harvested from the primary CFC 
assay (p?0.05,  
 
Fig 4.5.2a: Replating (Secondary) of colony forming cells: The graph illustrates the number of 
colonies obtained by replating the 1X106 cells harvested form the primary colony forming cell assay 
(section 4.5.1). The ?NRPID-HPIP-YFP transduced cells showed a significant increase in 
granulocytic colonies (p ? 0.05, n = 6) and a decrease in macrophage colonies (p ? 0.01, n = 6) as 
compared to control YFP (indicated with red lines). An increase in more primitive GM colonies was 
observed in ?NRPID-HPIP- YFP transduced cells compared to HPIP-WT and control YFP, but was 
non-significant.  
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Fig 4.5.2b: Replating (Tertiary) of colony forming cells: The graph illustrates the number of 
colonies obtained by replating the 1X106 cells harvested form the secondary colony forming cell 
assay (fig 4.5.2a). The values shown in above figure are normalised to a total number of 1X106 input 
cell number (obtained from a secondary CFC) per experimental group. The ?NRPID-HPIP-YFP was 
able to generate again G, M and GM colonies. In contrast the HPIP-WT and control YFP cells could 
only generate small clusters of megakaryocytes.  
 
n=6) as compared to control YFP with 6 (+1.6) colonies per 1X106 cells harvested 
from the primary CFC assay and HPIP-WT that showed 5 (+2) colonies per 1X106 
cells harvested from the primary CFC assay.  
 In addition, the constitutive expression of ?NRPID-HPIP in hCB CD34+ cells 
induced a  decrease in the number of megakaryocytic colonies (5±1.3 colonies per 
1X106 cells harvested from the primary CFC assay) (p?0.01, n=6) as compared to 
the colonies generated by expression of the control YFP (17.55±4.22 colonies per 
1X106 cells harvested from the primary CFC assay). There was an average 
increment of 60% of granulocytic colonies and a decrease of 67% in number of 
megakaryocytic colony formation by the expression of ?NRPID-HPIP in hCB 
CD34+ cells in replating assay as compared to the colonies generated by 
expression of HPIP and control YFP in hCB CD34+ cells.  
 At the end of the secondary CFC assays, half of the harvested cells were 
replated into 2 methylcellulose dishes (1/4 number of cells from secondary CFC 
assay per tertiary CFC assay) and the average number of colonies generated were 
scored after 14 days of incubation (Fig. 4.5.2b). The expression of ?NRPID-HPIP 
in transduced hCB CD34+ cells formed on an average of 27.45 (± 3.41) total 
colonies per 1X106 cells harvested from the secondary CFC assay in the tertiary 
replating while there were no colonies observed in control YFP. The former cells 
could sustain the formation of granulocytic colonies (17.5 ± 3.2), megakaryocytic 
colonies (1.5 ± 0.78) and mixed GM colonies (10.5 ± 2.6) per 1X106 cells harvested 
from the secondary CFC assay. The expression of ÄMBR-HPIP in transduced hCB 
CD34+ cells generated on an average 17.5 (±1.5) total colonies per 1X106 cells 
harvested from the secondary CFC assay and all of them were megakaryocytic 
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colonies. There were small clusters of cells to no colonies observed in the case of 
HPIP-WT and YFP.  
 
4.6. B-Lymphoid progenitor in vitro assay 
 
In an in vitro B-lymphoid progenitor assays, a total number of 1x104 hCB 
CD34+YFP+ cells were sorted for each experimental group (hCB CD34+ cells 
transduced with HPIP-WT, ?NRPID-HPIP-YFP, ?MBR-HPIP-YFP and YFP) and 
co-cultured with MS-5 feeder with two different cytokine cocktails: in the first set of 
co-culture the cells and feeder was supplemented with a cocktail of three cytokines 
(SCF, IL-2, IL-15) for a period of 4 weeks. Every week a half medium change was 
performed without disturbing the experimental cells that were sticking to the MS-5 
feeder layer. The total number of harvested cells, from the 10,000 initially plated 
cells was calculated at the end of the four weeks in culture.  
The HPIP transduced hCB CD34+ cells increased to 2.9x105 ± 2x105 (with >20 
fold increase in cell number as compared to initially plated 10,000 cells, n=4, p= 
ns), the ?NRPID-HPIP transduced hCB CD34+ cells decreased to 8983 ±230 cells 
(with <1 fold decrease in cells number as compared to initially plated 10,000 cells, 
n=4, p ? 0.05)),  the ?MBR-HPIP transduced hCB CD34+ cells increased to 
2.4x104 ± 1.5x104 cells (with >2 fold increase in cell number as compared to initially 
plated 10,000 cells, n=4, p=ns) and the YFP transduced hCB CD34+ cells 
increased to 3x104 ± 4300 cells (with >3 fold increase in cell number as compared 
to initially plated 10,000 cells, n=4)(Table 4.6a).  
Further we tested the fractions of cells with various lymphoid and myeloid 
surface markers, in the bulk harvested cells, from each experimental arm. The 
HPIP transduced hCB CD34+ cells generated an increase observed in the absolute 
number of CD34+ CD38 low/-cells (960 ± 615 cells, p=ns), a significant increase was 
observed in the proportion of the CD10+ cells (2328 ± 1292 cells, p?0.05), and 
CD19+ cells (4179 ± 2558 cells, p?0.05) as compared to the absolute number of 
cells generated by control YFP transduced hCB CD34+ cells (Table 4.6a).  
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In the second setting, the feeder layer was supplemented with six cytokines 
(SCF, IL-2, IL-15, IL-7, FLT3-L, and TPO), and the cells were cultured for a period 
of four weeks. For establishing this biphasic culture a total number of 1x104 CB 
CD34+YFP+ cells were sorted for each experimental group (hCB CD34+ cells 
transduced with HPIP-WT, ?NRPID-HPIP-YFP, ?MBR-HPIP-YFP and YFP). Every 
week a half medium change was performed without disturbing the experimental 
cells that were bonded to the MS-5 feeder layer. The total number of harvested 
cells (from 10,000 initially plated cells), were calculated at the end of four weeks for 
each culture.  
The HPIP transduced hCB CD34+ cells increased to 3.8x104 ± 7461 cells in 
number (with ?3.8 fold increase in cell number as compared to initially plated 
10,000 cells, n=5), the ?NRPID-HPIP transduced hCB CD34+ cells increased to 
3x104 ± 9129 cells in number  (with ?3 fold increase in cells number as compared 
to initially plated 10000 cells, n=4),  the ?MBR-HPIP transduced hCB CD34+ cells 
increased to 5.2x104 ± 8052 cells in number (with ?5.2 fold increase in cell number 
as compared to initially plated 10,000 cells, n=4) and the YFP transduced hCB 
CD34+ cells increased to 4.9x104 ± 6461 cells in number (with >4.9 fold increase in 
cell number as compared to initially plated 10,000 cells, n=4).  
The constitutive expression of HPIP- WT showed a significantly increased 
absolute number of the CD10+ (p?0.01, n=5), CD15+ (p?0.05, n=5) cells as 
compared to the absolute number of cells in the case of control YFP transduced 
hCB CD34+ cells (n=5)(Table 4.6b). The ?NRPID-HPIP transduced hCB CD34+ 
cells did not show any  significant changes in the number of CD33+ (p=ns, n=4) but 
could significantly increased the absolute number of CD15+ (p?0.05, n=4) cells as 
compared to the proliferation in the case of control YFP transduced hCB CD34+ 
cells (n=5)(Table 4.6b). The ?MBR-HPIP transduced hCB CD34+ cells also did not 
show any significant changes in the absolute number of cells with different surface 
markers expressing cell fractions, as compared to the cell proliferation in the case 
of control YFP transduced hCB CD34+ cells. 
Results 
 76 
 
 
Table 4.6a: The table illustrates the development of hCB CD34
+
 cells expressing HPIP-WT, 
?NRPID-HPIP-YFP, ?MBR-HPIP-YFP, and YFP in a 3 cytokine supplemented setup of the B-
lymphoid assay.   
hCB 
CD34+ 
cells 
transdu
ced  
with 
Average 
Number 
of  
hCD45+ 
cells 
generate
d 
(no. of 
cells ± 
SEM) 
(% 
proportio
n of YFP+ 
cells) 
Average 
Number 
of hCD34+ 
CB38low/- 
cells 
(no. of 
cells ± 
SEM) 
(% 
proportio
n of YFP+ 
cells) 
Average 
Number 
of hCD10+ 
cells 
(no. of 
cells ± 
SEM) 
(% 
proportio
n of YFP+ 
cells) 
 
Average 
Number of 
hCD19+ 
cells 
(no. of cells 
± SEM) 
(% 
proportion 
of YFP+ 
cells) 
Average 
Number of 
hCD15+ 
cells 
(no. of cells 
± SEM) 
(% 
proportion 
of YFP+ 
cells) 
Average 
Number 
of hCD33+ 
cells 
(no. of 
cells ± 
SEM) 
(% 
proportio
n of YFP+ 
cells) 
HPIP-
WT 
n=4 
2.9x10
5
± 
2x10
5 
(96.36%) 
•p=ns 
960 ± 615
 
(0.97%) 
p=ns 
2328 ± 
1292 
(2%) 
p?0.05 
4179 ± 2558 
(1.6%) 
p?0.05 
712± 477 
(0.7%) 
p = ns 
2.6x10
5
± 
x10
5 
(83.5%) 
p=ns 
?NRPID-
HPIP 
n=4 
8983 ±230 
(90%) 
p?0.05 
 
306 ± 121 
(3%) 
p=ns 
74 ±47 
(0.7%) 
p=ns 
13± 9 
(0.5%) 
p=ns 
387.5±172.6 
(2.87%) 
p=ns 
8432± 
418.3 
(84%) 
p=ns 
?MBR-
HPIP 
n=4 
2.4x10
4 
± 
1x10
4 
(96.8%) 
p=ns
 
 
196 ± 20.7 
(1.7%) 
p=ns 
170 ±  88 
(1.2%) 
p=ns 
9.9 ± 8 
(0.5%) 
p=ns 
40.5±24.4 
(3.4%) 
p?0.05 
27293 
±17523 
(95.7%) 
p=ns 
YFP 
n=4 
6x10
4
 ± 
4298 
(95.18%) 
 
246 ±31 
(0.4%) 
218 ± 55 
(0.2%) 
 
 
15 ± 2 
(0.3%) 
201±48 
(0.9%) 
 
5.2x10
4
 ± 
3547 
(85.2%) 
• P values refer to the significant differences between the absolute numbers of cells with respect to  control YFP. 
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Table 4.6b: The table illustrates the development of hCB CD34
+
 cells expressing HPIP-WT, 
?NRPID-HPIP-YFP, ?MBR-HPIP-YFP, and YFP in a 6 cytokine supplement setup of B-
Lymphoid assay.  
hCB 
CD34+ 
cells 
expressi
ng 
Average 
Number of  
hCD45+ 
cells 
generated 
(no. of cells 
± SEM) 
Average 
Number 
of hCD34+ 
CD38Low/-
cells 
(no. of 
cells ± 
SEM) 
Average 
Number 
of 
hCD10+ 
cells 
(no. of 
cells ± 
SEM) 
Average 
Number of 
hCD19+ 
cells 
(no. of 
cells ± 
SEM) 
Average 
Number of 
hCD15+ 
cells 
(no. of 
cells ± 
SEM) 
Average 
Number 
of 
hCD33+ 
cells 
(no. of 
cells ± 
SEM) 
HPIP 
WT 
N=5 
3.8x10
4
 ± 
7461 
(99%) 
•p=ns 
977 ± 352 
(3.5%) 
p=ns 
 
32166 ± 
0830 
(1.2%) 
p?0.01 
301 ± 113 
(2.3%) 
p=ns 
294 ± 109 
(3.8%) 
p?0.05 
 
36688 ± 
7723 
(95%)
 
p=ns 
?NRPID-
HPIP 
N=4 
3x10
4
 ± 
9129 
(95.32%) 
p=ns 
1634 ± 
943 
(2.5%) 
p=ns 
172 ± 
172 
(0.8%) 
p=ns 
517 ± 517 
(0.2%) 
p=ns 
2242 ± 980 
(7.8%) 
p?0.05 
26629 ± 
7791 
(90.7%) 
p=ns 
?MBR-
HPIP 
N=4 
5.2x10
4
 ± 
8052 
(97.37%) 
p=ns 
3208 ± 
2856 
(1.1%) 
p=ns 
938 ±  
487 
(1.6%) 
p=ns 
2384± 2384 
(3.17%) 
p=ns 
1355 ± 
1028 
(3.3%) 
p=ns 
49762 ± 
751 
(95.90%) 
p=ns 
YFP 
N=5 
4.9x10
4
 ± 
6461 
(97.37%) 
2560 ± 
118 
(2%) 
 
210 ± 5 
(0.4%) 
 
1263 ± 61 
(3.8%) 
30 ± 2 
(0.1%) 
 
47828 ± 
522 
(94%) 
 
• P values refer to the significant differences between the absolute numbers of cells w.r.t control YFP. 
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4.7. Long term culture initiating cell assay (LTC-IC) in vitro. 
 
In an attempt to test the influence of HPIP-WT expression on the maintenance of 
primitive human progenitors in long-term cultures, we performed the LTC-IC assay: 
highly purified 1x104  CD34+ YFP+, CD34+ HPIP-YFP+, CD34+ ?NRPID-HPIP-YFP+ 
and CD34+ ?MBR-HPIP-YFP+ cells were seeded on a mixture of M2-10B4-J-
GCSF-tkneo-J-IL3-hytk fibroblast and SL/SL-J-SF-tkneo-J-IL3-hytk fibroblast 
feeder cells engineered to produce human SF, IL-3, and G-CSF under LTC-IC 
conditions. The bulk LTC-IC cultures were carried out for a period of 6 weeks with 
a weekly half medium change. At the end of week 6 all the cells were harvested 
from the dishes and the number of cells obtained was registered. These cells were 
resuspended in Methocult-H4434 and plated in methylcellulose dishes (one half of 
the total number of cells obtained in each dish). Colonies generated after 16-20 
days were scored. The average number of CFC per 1x106 initially plated cells was 
calculated (see methods, p-53&54). The expression of HPIP-WT in hCB CD34+ 
cells increased the CFC output by 10 fold with an average value of 14315 ± 87 
colonies per 1X106 cells initially plated versus the colonies obtained by the 
expression of YFP control alone, with an average number of 1371.4 ± 672 colonies 
per 1x106 cells  initially plated (n=8, p?0.05)Table 4.7)   
 The cells expressing ?MBR-HPIP-YFP mutant form did not show an increase 
in the number of colonies generated equivalent to 1337 (±493) colonies per 1X106 
cells as compared to the control YFP (n=3, p=ns). The cells expressing ?NRPID-
HPIP-YFP mutant form showed a decrease in the number of colonies generated 
with an average number equivalent to 424 (± 64) (p=ns) colonies per 1X106 cells 
as compared to the control YFP.  
 The total yield of LTC-IC was calculated relative to the number of CFC 
obtained per 1x106 initially plated cells. The average CFC output per LTC-IC115 has 
been standardized to a calculated factor of 8. The CFC output per million cells was 
divided by 8 to obtain the absolute number of LTC-IC generated at the end of the 
co-cultures, after 6 weeks. The number of LTC-IC generated per million cells for 
the cells expressing HPIP-WT was calculated. The expression of HPIP-WT in  
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Table 4.7 shows the average number of LTC-IC and CFC generated per million of initially 
plated cells in bulk LTC-IC assay in vitro. 
The exp er imental form 
ret rov irally  t ransduc ed in hCB 
CD34+ cel ls 
Average number o f CFC 
per  1x106 init ia l ly  plat ed 
c el ls (± SEM) 
Average number o f LTC-
IC generat ed per  mi ll ion 
c el ls (± SEM) 
HPIP-WT-YFP,  (n=8) 14315 ± 87 *545 ± 169 
?NRPID-HPIP-YFP (n=3) 424 ± 64 53 ± 8 
?MBR-HPIP-YFP (n=3) 1338 ± 493 180.4 ± 58 
YFP (n=8) 1371.4 ± 672 165.8 ± 67 
*Significance calculated with respect to control YFP (p?0.05) 
 
 
Figure 4.7: Long term culture initiating cell assay in vitro. The graphs show the long term 
culture initiating cells (LTC-ICs) obtained with the constitutive expression of WT and mutant forms of 
HPIP in hCB CD34+ cells. The WT and mutant HPIP forms were seeded (10,000 cells per 
experimental group) on a mixture of M2-10B4-J-GCSF-tkneo-J-IL3-hytk fibroblasts and SL/SL-J-SF-
tkneo-J-IL3-hytk fibroblasts feeder cells and co-cultured using LTC-IC medium and (see methods, 
53&54), for 6 weeks. Every week a half medium change was performed not disturbing the cells 
sticking to the feeder layers. At the end of 6 weeks al the cells were harvested, counted and 
suspended in Methocult-H4434, and plated into methylcellulose dishes. After 19-20 days in 
methylcellulose culture, colonies were scored and LTC-IC bulk frequency was calculated. hCB 
CD34+ cells transduced with HPIP-WT showed a significant increase of LTC-IC per 1x106 cells (A) 
(p?0.05, n=8) as compared to YFP control (indicated with red line). 
 
hCB CD34+ cells increased the number of LTC-IC by 2.5 fold, with an average 
number of 545 (±169) bulk LTC-IC per million cells initially seeded as compared to 
the control YFP with an average number of 102 (±33) bulk LTC-IC per million cells 
(n=8, p?0.05). The mutant forms of HPIP-WT did not show any significant changes 
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in the calculated absolute number of LTC-IC per million cells as compared to the 
control YFP.  
 
 4.8. Double transductions with HPIP-WT-YFP and HOXB4-WT-GFP 
construct. 
 
 To evaluate whether genes such as HOXB4 are able to collaborate with HPIP, 
double transductions were performed in primary cord blood progenitors. However, 
there were no significant differences found in in vitro Colony forming cell (CFC) 
assays or Long term culture initiating cell (LTC-IC) assays for CBCD34+HPIP WT-
YFP+/HOXB4-GFP+ and the control vector YFP+/GFP+ (Figure 4.8). The double 
transduction experiment demonstrated that there was no impact of HOXB4-WT 
constitutive expression on HPIP-WT function in this functional assay setup of CFC 
and LTC-IC. 
In order to test the impact of constitutive expression of HPIP-WT and HOXB4-
WT together on the growth of clonogenic progenitors 3300 cells triple positive for 
HPIP- WT-YFP, HOXB4-WT- GFP and CD34 expression were suspended in 
methylcellulose-H4434 (Methocult-H4434) and plated into 2 methylcellulose dishes  
(1000 CD34+YFP+GFP+cells/ dish). In parallel separate CFC assays were carried 
out with HPIP-WT-YFP only, HOXB4-WT-GFP only expressing cells and YFP only 
or YFP/GFP expressing cells as control. The methylcellulose dishes were scored 
on the 15th day for colonies. The outcome of colony formation is illustrated in the 
figure 4.8b. There were no significant synergistic effects observed on the total 
number of colonies and the types of colonies generated in double transduced cells 
as compared to the control YFP. 
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Figure 4.8: Double transductions with HPIP-WT and HOXB4 construct. The above acquisition 
plots illustrate a simple setup of sorting double transduced cells expressing HPIP-WT-YFP and 
HOXB4-GFP in primary cord blood cells. Only YFP and GFP double positive cells were gated (gate 
R2). Gated cells of R2 were further gated to define CD34+APC+ cells. These triple positive cells 
CD34+YFP+GFP+ were sorted for different in vitro assays such as CFC and LTC-IC.  
 
Figure 4.8b: CFC assays with double transduced hCB CD34
+
 cells. The graph illustrates the 
number of colonies obtained by the hCB CD34+ cells transduced with HPIP-WT, HOXB4-WT, 
HPIP- WT+ HOXB4-WT and control YFP vectors. There were no significant changes observed in 
the colony numbers of E, G, M, GM and GEMM or total colony numbers in the CFC assay done with 
double transductions (n=3, p=ns).  
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4.9. Analysis of WT and HPIP mutant expression functions in the 
xenotransplant NOD/SCID model. 
 
To evaluate the effects of constitutive expression of HPIP-WT and its mutant 
forms, on the developmental pathways of human haematopoietic progenitor cells in 
vivo, xeno-transplantations of hCB CD34+ transduced with HPIP-WT, ?NRPID-
HPIP-YFP, ?MBR-HPIP-YFP and YFP, were performed in NOD/SCID mice.   The 
hCB CD34-YFP+ and hCB CD34-YFP- cells were co-injected with the CD34+ 
transduced cells to support their engraftment did you irradiate them?. The initial 
number of cells taken for injections (double positive for hCB CD34 and YFP) for 
bulk in vivo assays was 2.0x104 hCB CD34+YFP+ cells for all the irradiated cohorts 
of mice. At the end of 6-8 weeks, mice were sacrificed and the engraftment of 
transduced human hCB cells (YFP+) and non-transduced human hCB (YFP-) cells 
was assessed by FACS. In order to characterize long-term engrafts in mice bone 
marrow, the multilineage differentiation of the engrafted hCB CD34+YFP+ cells 
(engrafts) was assessed. Figure 4.9 illustrates how the analysis was performed.  
 
4.9.1. Engraftment of transduced hCB CD34+ cells in the bone 
marrow of NOD/SCID mice.  
 
 Lympho-myeloid engraftment was defined by the presence of at least 5 human 
transduced CD19+ B cells plus at least 5 human transduced myeloid CD15+ cells 
per 2?104 CD45+ human cells analyzed from harvested mice bone marrow. The 
harvested BM cells from all the cohorts of xenotransplanted mice, that were 
engrafted, were analyzed for expression of a panel of surface markers (CD45, 
CD34, CD38, CD15, CD19, CD33, CD36, CD41a, CD71, CD10, CD133, CD117 
and Glycophorin A) to distinguish the different myeloid, lymphoid or erythroid 
fractions of human haematopoietic cell lineages.  
 The engraftment levels of YFP+ human haematopoietic cells, at week 6, 
ranged from 0.36 to 8.6 % of CD45+ YFP+ for the HPIP-WT cohort  (n=6) and from 
0.8-13.07 % for the YFP control group (n=8). Both groups showed lymphoid  
Results 
 83 
 
 
 
Figure 4.9.: Representative acquisition dot plots from the cells harvested from the BM of the 
NOD/SCID mice. The dot graphs above are a simple illustration of the criteria that was used to 
assess the presence and repopulation of engrafted human haematopoietic cells in NOD/SCID mice. 
After the harvest of NOD/SCID bone marrow, the cells were stained for hCD45 (PE) cell surface 
marker. In the dot graph a mix of mouse and human cells that were gated as R1(shown in green 
box); (A) all the cells gated in R1 were further separated into three different gates R2 (shown in 
turquoise box), R3 (shown in pink box) and R4 (shown in red box); (C) the cell population in R2 
region presents murine bone marrow cells; (B) The cell population in R3 region is the human CD45+ 
YFP- cell population and (C) the cell population gated in R4 region is the hCD45+YFP+ cells. 
Similarly all the other staining were analysed in engrafted mice using only the hCD45+YFP+ human 
compartment of cells. As an internal control for comparison with the transduced compartment the 
hCD45+YFP- compartment was used. In this experimental set up different cell surface markers were 
used to determine the differentiation stage of cells such as e.g. CD34 (PE)/CD38 (APC). 
 
predominance of engrafted human cells with lymphoid/myeloid ratios (CD19/CD15) 
ratio ranging between 3 to10. Similarly, engraftment levels were measured in the 
cohorts of mice transplanted with ?NRPID-HPIP-YFP and ?MBR-HPIP-YFP 
expressing cells  At week 8, the engraftment levels of YFP+ human cells ranged 
from 0.54 to 2.41% for ?NRPID-HPIP-YFP (n=4) and were 2.4% for ?MBR-HPIP-
YFP(n=1). These results demonstrate that a long-term lymho-myeloid engraftment 
in all experimental groups was achieved, indicating efficient gene transfer into long-
term repopulating stem cells (Table 4.9.1). 
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Table 4.9.1: Multilineage engraftment generated by the hUCB CD34
+
 Lin
-
 cells transduced with 
WT and mutant forms of HPIP. 
° Representative of gates R3and R4, as shown in figure 4.9 above. 
°° Representative of gate R4 only, as shown in figure 4.9 above. 
 
 ?NRPID-HPIP–YFP expression decreased the human cell engraftment into 
NOD/SCID mice. Of 31 mice that received a transplant, only 9 mice (29%) 
exhibited human cell engraftment after 6-8 weeks and the engraftment levels were 
low (medien=1.9%, range=0.58%-3.42%) relative to the YFP control (medien=7.71, 
range=0.35%-13.8%).   
Lymphoid engraftment in 
NOD/SCID mice 
Myeloid engraftment in NOD/SCID mice 
 
% of CD45
+
CD19
+
 cells % of CD45
+
CD15
+
 cells % of CD45
+
CD33
+
 cells Cohort 
 °° % of all 
YFP
+ 
and 
YFP
-
 cells (±± 
SEM) 
°°° % of YFP
+
 
only ( ±± 
SEM) 
°° % of all 
YFP
+ 
and 
YFP
-
 cells ±± 
SEM 
°°° % of YFP
+
 
only ±± SEM 
°° % of all 
YFP
+ 
and 
YFP
-
 cells ±± 
SEM 
°°° % of 
YFP
+
 only 
±± SEM 
HPIP WT-YFP   
(n=8) 
53.24±±1.17 82.69±±4.29 8.45±±4.5 36.26±±3.79 34.88±±8 69.16±±7.18 
?NRPID-
HPIP-YFP     
(n=4) 
28.02±±2.24 20.34±±5.77 10.04±±0.7 7.35±±1.5 15.0±±4.3 53.36±±9.89 
?MBR-HPIP-
YFP        (n=1) 
33.51 16.57 2.41 18.67 8.01 61.08 
YFP             
(n=6) 
59.89±±5.88 65.00±±12 11.21±±5.0 14.50±±4.8 27.99±±9.0 70.68±±7.37 
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 4.9.2. The assessment of the lymphoid/ myeloid ratio in vivo. 
 
 Balanced HSCs repopulate peripheral white blood cells in the same ratio of 
myeloid to lymphoid cells as seen in unmanipulated mice (on average about 15% 
myeloid and 85% lymphoid cells, or 3?ñ?10). In the recipients of transduced HPIP-
WT-YFP, the number of CD15+
 
Myeloid cells generated was found to be 2.5 fold 
higher thanthe CD15+ YFP+
 
cells in the BM of the control YFP mice. The 
lymphoid/myeloid ratio was 1.8, in the case of HPIP-WT as compared to 4.4 in the 
control YFP mice (n=6, p?0.05) (Fig 4.9.2). The expression of the ?MBR-HPIP 
mutant form of HPIP resulted even in an inversion of the lymphoid/myeloid ratio of 
0.8. The expression of the ?NRPID mutant form of HPIP did not show any 
significant inversion of CD19/CD15 ratio as compared to the control YFP or HPIP-
WT (slightly lower value of 2.7 as compared to YFP control (n=4, p=ns). Thus, 
constitutive expression of the WT HPIP significantly reduced the lymphoid/myeloid 
ratio of human engrafted cells depending on its ?NRPID domain.  
 
4.9.3. Short term (hSTRCs) and long term (hLTRCs) repopulating 
populations in NOD/SCID bone marrow. 
 
The harvested bone marrow from all the cohorts of NOD/SCID mice was 
analysed in details by staining the CD45+ cell population with various hSTRCs and 
hLTSCs classifying surface markers. At least 5x105 cells were chosen to be 
stained with antibodies specific for surface antigens of CD34, CD38, cKIT (CD117) 
and CD133 expression. The proportion of CD34+ cells in the engrafts transduced 
with HPIP- WT-YFP showed no significant changes with a mean value of 43.7% 
(CD34+YFP+ cells, p?0.05, n=6) as compared to 42.7% in the control mice (n=6).  
The proportion of CD34+ cells in the engrafts transduced with ?NRPID-HPIP-
YFP was significantly decreased with a mean value of 14.45% (CD34+YFP+ cells; 
p?0.05, n=4) as compared to the YFP control. The proportion of CD34+ cells in the 
engrafts transduced with ?MBR-HPIP-YFP also did not show any significant 
changes with a mean value of 34.85% (CD34+YFP+ cells, p=ns, n=1), as compared 
to the proportion of CD34+ cells in the engrafts transduced with YFP with a value of 
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42.7% (n=6)(Fig 4.9.3a).  The hCD34+ cells were checked for the presence of the 
early differentiation marker CD38. The proportion of cells, expressing CD34+ and  
 
Figure 4.9.2: The lymphoid / myeloid cell ratio assessment. The figure demonstrates the 
calculated lymphoid to myeloid cell ratio (CD19+/CD15+), that was assessed in the bone marrow of 
engrafted NOD/SCID mice in each experimental group. (A)After 8 weeks of transplantation with hCB 
CD34+YFP+ cells, the bone marrow of NOD/SCID mice was harvested and checked for engraftment. 
The CD45+ YFP+ cell proportions from each of the engrafted mice were analysed for the presence of 
CD19+ and CD15+ surface markers. Engrafted mice transplanted with CB CD34+ HPIP-WT-YFP+ 
cells showed a significant change in the ratio between lymphoid and myeloid cells of 1.8 (n=8, 
**p?0.05) as compared to the YFP control with 4.4 (n = 6), indicating a generation of a more myeloid 
biased population by HPIP-WT.  
 
CD38+ 31(hCD34+CD38+, hSTRCs) was found to be significantly increased in 
engrafts transduced with HPIP-WT with a mean value of 43.16% (p?0.05, n=6) as 
compared to the YFP control with a mean value of 22.39% (n=6)(Fig 4.9.3a). This 
effect of HPIP was depending on the ?NRPID domain as in ?NRPID-HPIP mice 
there was a significant decrease in hSTRCs with a mean value of 7.69% (p?0.01, 
n=4) compared to HPIP- WT and the YFP control. The results showed that 
expression of HPIP-WT or its mutant forms can significantly change the 
proportions of the hSTRCs in vivo. 
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The second analysis focused on the proportions of hLTRCs in the 
xenotransplated NOD/SCID mice with WT and mutant HPIP transduced hCB 
CD34+ cells (Fig. 4.9.3b). The percentage of CD45+YFP+ cells in all the engrafts 
was checked for the presence of primary haematopoietic progenitors (HPCs), 
expressing the surface marker hCD34+CD38-Lin-. The proportion of cells with 
CD34+CD38- phenotype was calculated. The proportion of hCD34+CD38- cells was 
found significantly decreased in the engrafts transduced with ?NRPID-HPIP-YFP 
cells with a mean value of 0.21% (p?0.05,n=6) cells, as compared to the control 
YFP with a mean value of 2.7% cells expressing hCD34+CD38-. The expression of 
HPIP-WT in the engrafts did not show any significant changes as compared to the 
control YFP expressing engrafts (fig 4.9.3b). 
The percentage of hCD45+YFP+ cells in all the engrafts was checked for the 
presence of haematopoietic progenitors (HPCs), expressing the surface marker 
cKIT+ (hCD117+). The proportion of hCD45+CD117+YFP+ cells was found 
significantly increased in the engrafts transduced with HPIP-WT-YFP cells with a 
mean value of 26.85% (p?0.05,n=6) cells, as compared to the control YFP with a 
mean value of 7.72% cells expressing cKIT. The expression of HPIP-WT in the 
engrafts increased significantly the number of hLTRCs by 3.4 fold as compared to 
the YFP control. No significant difference was observed in the proportion of most 
primitive haematopoietic cells31 (hCD34+CD38-, STRC-ML) in all the engrafts 
analysed above. Interestingly, there was an increase in the proportions of CD133 
expressing cells in the engrafts of ?NRPID-HPIP-YFP transduced hCB cells with a 
mean value of 14.9% cells (p?0.01, n=4) as compared the control YFP with a value 
of 0.4% cells (n=6), however there were no significant differences observed in the 
case of HPIP-WT as compared to the control YFP. 
 The expression of ?NRPID-HPIP-YFP (p?0.05, n=4) significantly decreased 
the number of hLTRCs by 3.4 fold as compared to the control YFP (n=6). The 
above results demonstrated a crucial role of the NRPID domain in making the stem 
cell fate decision at the haematopoietic multiprogenitor cell level. The deletion of 
this domain strongly affected the proportion of human long term repopulating cells 
(hCD34+ and hCD117+ cells) in vivo, generating a lower number of hLTRCs. Also 
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this deletion induced a decrease in human short term repopulating cells 
(hCD34+38+ cells) in vivo,. The results implicate that HPIP-WT is a putative 
regulator of short  
 
 
Figure 4.9.3a: Short term repopulating cells in vivo. The above graph illustrates of the proportion 
of short term repopulating cells in the BM of engrafted NOD/SCID mice. HPIP expression increased 
significantly the proportion of short term repopulating cells (CD34+CD38+ cells) in vivo (**p?0.05). 
The mutant form of HPIP, ?NRPID-HPIP significantly decreased the proportion of hSTRCs in the 
BM of engrafted NOD/SCID mice as compared to the YFP control and HPIP-WT (**p?0.05).  
 
Figure 4.9.3b: Engraftment of human progenitor cells in NOD/SCID mice. The graph illustrates 
the proportions of the human CB CD45+, CD34+, CD117+, and CD133+ transduced cells engrafted in 
the bone marrow of NOD/SCID mice 
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term repopulating cells and progenitor cells in vivo and that for this effect the 
?NRPID domain is crucial.  
  
4.9.4. The effect of constitutively expressed WT and mutated HPIP 
on the multilineage repopulation of human haematopoietic 
cells in NOD/SCID engraft model. 
 
 In an attempt to characterize the function of WT, or mutated HPIP on human 
haematopoietic differentiation, the harvested BM cells were evaluated for 
expression of a panel of surface markers (CD45, CD34, CD38, CD15, CD19, 
CD33, CD36, CD41a, CD71, CD10, CD133, CD117 and Glycophorin A) to quantify 
the myeloid, lymphoid or erythroid human subpopulations.  
The proportion of hCD45+YFP+ cells expressing CD19 did not differ between 
HPIP- WT mice with a mean value of 68.55% cells (p=ns, n=6), as compared to the 
YFP control mice with a mean value of 65.06%. A very significant decrease in the 
proportion of hCD45+CD19+YFP+ cells was observed for the ?NRPID-HPIP cohort 
with a mean value of 20.34% cells (p?0.01, n=4), as compared to the HPIP-WT 
and control YFP(fig 4.9.4). Also ?MBR-HPIP mice showed a significant decrease 
of hCD45+ CD19+ YFP+ cells with a mean value of 19.59% cells (n=1), as 
compared to the HPIP-WT and control YFP. The proportion of hCD45+CD71+YFP+ 
cells did not show any significant difference between HPIP-WT, with a mean value 
of 41.8% hCD45+ CD71+YFP+ cells (p=ns, n=6), compared to the control with a 
mean value of 32.4% (n=6).  
However a significant differences were observed in the proportion of the 
hCD45+CD71+YFP+ cells in ?NRPID-HPIP-YFP mice with a mean value of 2.64% 
hCD45+CD71+YFP+ cells (p?0.01, n=4), and in ?MBR-HPIP mice with a mean 
value of 3.39% hCD45+ CD71+YFP+ cells (n=1), as compared to the HPIP-WT and 
control YFP. There was a 4 fold decrease (p?0.01) in the proportion of human 
erythroid cells in NOD/SCID mice transplanted with CB expressing both the mutant 
forms of HPIP as compared to the WT HPIP and control YFP. However we did not 
observe any significant differences between the case of HPIP-WT and YFP control.  
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The proportion of hCD45+YFP+ cells expressing CD15 were significantly 
increased by HPIP-WT expression with a mean value of 37.26% of 
hCD45+CD15+YFP+ cells (p?0.05,n=6), as compared to the YFP control with a  
 
Figure 4.9.4: Multilineage repopulation of human haematopoietic cells in bone marrow of 
NOD/SCID mice. The above graph illustrates the percentage of transduced YFP+ human cells of 
the different lineages engrafted in NOD/SCID bone marrow:  lymphoid lineage (hCD19+, hCD10+), 
myeloid lineage (hCD15+, hCD33+, and hCD36+), and erythroid lineage (hCD71+). The bone marrow 
from engrafted mice was harvested and stained for various cell surface markers to quantify the 
proportion of different cell lineages in the YFP+ compartment of the whole bone marrow. A 
significant decrease in the number of cells expressing CD19 and hCD10 was observed in the case 
of human haematopoietic cells transduced with ?NRPID-HPIP-YFP (n=4) and ?MBR-HPIP-YFP 
(n=1) mutant forms of HPIP as compared to HPIP-WT (n=6) and control YFP (n=6, *p?0.05). There 
was a significant decrease observed in the number of cells expressing erythroid cell specific marker 
hCD71, on all the human haematopoietic cells transduced with mutant forms of HPIP (fold decrease 
= 4, **p<0.01).  
 
mean value of 15.59% of hCD45+CD15+YFP+ cells (n=6). A significant 
decrease in the proportions of hCD45+CD15+YFP+ cells was seen in the case of 
?NRPID-HPIP-YFP transplanted mice with a mean value of 7.38% of 
CD45+CD15+YFP+ cells (p?0.01, n=4), as compared to the HPIP-WT and the 
control.  
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There were no significant changes observed in the proportions of 
hCD45+CD33+YFP+ or hCD45+CD36+YFP+ cells between ?NRPID-HPIP-YFP and 
?MBR-HPIP-YFP as compared to the HPIP-WT and YFP control. Also we did not 
observe significant differences between the proportions of hCD45+CD33+YFP+ or 
hCD45+CD36+YFP+ cells in the case of HPIP-WT and YFP control. The results 
indicate that WT and mutant HPIP protein can deregulate the developmental 
pathways of human haematopoiesis.  
 
4.9.5. Limiting Dilution Assay (LDA) in NOD/SCID mice: 
Quantification of SCID Repopulating (SRC) cell frequency.  
 
To determine if WT or mutant HPIP expression affects the frequency of SCID 
repopulating cells (SRC) in the NOD/SCID xenotransplantation model, limiting 
dilution assays with the CB CD34+ cells transduced with the HPIP-WT and control 
YFP, were carried out. For this hCB CD34+YFP+ cells, that were retroviral 
transduced with HPIP-WT or the empty control vector, were injected intravenously 
in cohorts of mice with different dilution of these cells. (Table 4.5.9a and Table 
4.5.9b).  
The mice were sacrificed after 6-8 weeks and the bone marrow was analysed. 
Based on the number of engrafted mice per cohort the frequencies were calculated 
by Poisson statistics using the L-CALC® software (StemCell Technologies Inc.). Four 
independent experiments were performed and the SRC frequency was calculated 
by pooling all the experiments together. The SRC frequencies was 1 in 31866 for 
HPIP- WT transduced CD34+ cells and 1 in 19098 YFP transduced CD34+ cells 
(n=4, p=ns, Table 4.9.5a).  
To determine if the deletion mutants form of HPIP, ?NRPID-HPIP-YFP affects 
the frequency of SCID repopulating cell (SRC), limiting dilution analysis in 
NOD/SCID mice were performed on a similar pattern as mentioned above. The 
hCB CD34+ cells were transduced with HPIP-WT-YFP, ?NRPID-HPIP-YFP and a 
control YFP in a single experiment. The mice were sacrificed after a period of 8 
weeks and the BM was analysed for multilineage engraftment. Based on these 
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limiting dilution results, the frequencies of SRC in the transduced hCB cells were 
calculated. The frequency of engraftment was 1 in 11348 for HPIP-WT, 1 in 36814 
for ?NRPID-HPIP-YFP and 1 in 32729 YFP only transduced CD34+ cells (p=n.s.).  
 
 Table 4.9.5: SRC frequencies of CB CD34+YFP+ were calculated by limiting dilution 
transplantation for HPIP-WT, ?NRPID-HPIP-YFP and the control YFP. 
Analyzed mice/Engrafted mice (n=1) 
 
Serial 
no 
Dilution/ Cell 
dose 
CB34
+
YFP
+
 cells 
YFP control 
(Number of analysed 
mice/engrafted mice) 
 
HPIP- WT 
(Number of analysed 
mice/engrafted mice) 
 
?NRPID-HPIP 
(Number of 
analysed 
mice/engrafted 
mice) 
 
 
1 
2 
3 
 
 
50000 
10000 
3000 
 
 
1/1 
3/1 
2/0 
 
3/3 
3/2 
2/0 
 
 
5/3 
3/2 
2/0 
 
 
 
Frequency of 
LTC-IC in Bone 
marrow of 
NOD/SCID 
mice 
 
1 in 32729 
 
 
1 in 13248 
 
 
1 in 36814 
 
 
Proportion 
(95% 
confidence 
interval) 
 
1/5656-1/99549 
 
1/3539-1/36392 
 
1/13914-
1/97402 
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4.10. Affymetrix differential gene expression profile 
 
4.10.1. Comparative analysis of gene expression:  HPIP-WT-YFP, 
?NRPID-HPIP-YFP and ?MBR-HPIP-YFP relative to control 
YFP transduced human cord blood CD34+ cells. 
 
In an attempt to provide a molecular basis for the observed functional differences, 
we analyzed the gene expression of CD34+ cells transduced with HPIP- reported 
here are based on four micro arrays, each profiling gene expression of hCB CD34+ 
cells transduced with HPIP-WT, ?NPRID-HPIP-YFP, ?MBR-HPIP-YFP or YFP 
cells, 48 hours after the end of transduction. At that time point the cells were 
harvested and hCD34+YFP+ cells were sorted out by FACS for each experimental 
group. RNA was prepared from each set of CD34+YFP+ cells. We analyzed the 
data by defining gene expression levels of hCB CD34+ cells transduced with YFP+ 
only as a baseline for comparison, and the relative differences in gene-expression 
levels (see methods, p-57)(Fig 4.10.1). 
Further, a numerical threshold of 1.5-fold was set to identify target genes, which 
were differentially expressed. This threshold was chosen, as a 1.5-fold difference 
can be validated by other assays such as Low Density Array and Q-RT-PCR. 
Based on these criteria, a comparative analysis showed that 28 genes were 
differentially expressed between HPIP-WT compared with hCD34+YFP+ control 
cells. Ten genes showed significantly decreased expression in CD34+ HPIP-WT-
YFP cells, whereas the expression of 18 genes was increased as compared to the 
YFP control (Fig 4.10.1).  
Among the differentially expressed genes specific groups of genes involved in 
different cellular pathways were found. Seven of the deregulated genes are 
involved in MAPK pathway namely: CD14, FGFR3, FLNA, FOS, HRAS, RAPIA 
and SOS1. Along with this many genes involved in cytokine-cytokine interactions 
were also differentially expressed, namely: CCL3, CXCL2, CXCL5, CXCR4, HGF, 
IL10RB, PF4 and TNFRSF19. Genes involved in CXCR/SDF1 axis/Pathway 
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namely: DPP4, HRAS, SOS1, and CXCR4.  The majority of the gene expressions 
mentioned in  
 
Figure 4.10.1: Heat map representative of Affymetrix differential gene expression profile. The 
heat map above illustrates the differential expression of genes in hCB CD34+ cells transduced with 
YFP only as a control, ?MBR-HPIP, ?NRPID-HPIP, and HPIP-WT. A differentially expression of 1.5 
fold (up or down regulated genes) compared to the YFP control was defined as threshold. The 
comparative expression profile shown here is an expression calculation with respect to the control 
YFP expression values. Downreglation or upregulation is shown by different colours as indicated. 
 
these pathways could be confirmed at Q-RT-PCR level. A few more genes with 
expression differences of > 2 fold e.g. FOSB, GZMB, SCARNA17, CHRM3, CNN3 
and ASS1 were confirmed by performing Q-RT-PCR in triplets using inventory 
express plates from Applied Biosystems (Table 4.10.1) 
Besides the above mentioned genes, there were significant differences observed in 
the gene expressions between human hCB CD34+ cells transduced with HPIP-WT 
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and the ?NRPID-HPIP mutant form. A comparative analysis carried out between 
expression arrays of HPIP-WT and its mutant form ?NRPID-HPIP-YFP showed, in 
total 186 genes that were differentially expressed. Out of these 186 genes there 
were 129 genes that were upregulated in the cells expressing ?NRPID-HPIP-YFP 
mutant form as compared to expression profile of the HPIP-WT expressing cells. 
In total, 14 genes showed a 1.5 to 2 fold higher expression in hCB CD34+YFP+ 
cells transduced with ?NRPID-HPIP-YFP, as compared to the cells transduced 
with HPIP- WT-YFP: these genes were namely: KRT1, PKIB, PPAP2A, PTX3, 
C3AR1, NARG1, FGFBP3, CCL3, C1orf43, CRISP2, ZNF618, GZMB, IL1RL1, and 
CCNA1. Another set of 10 genes showed a 1.5 to 2 fold lower gene expression in 
the Affymetrix expression analysis carried out for the hCB CD34+YFP+ cells 
transduced with ?NRPID-HPIP-YFP mutant form as compared to the HPIP-WT 
transduced cells. These genes were namely: TGFB1I1, CHRM3, SLC16A3, ASS1, 
TNS1, WSB1, SCARNA17, ASNS, CYP1A1, and PLXNA1. In the tables 4.10.1a 
and 4.10.1b, all the genes that were differentially expressed between HPIP-WT 
and the mutant ?NRPID-HPIP compared to the genes with respect to the 
expression of genes in the case of control YFP only. Functions of some of the 
genes are explained in table 4.10.1b. 
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Table 4.10.1: Differential gene expression in hCB CD34
+
 cells transduced with WT and 
?NRPID-HPIP mutant form of HPIP as compared to the YFP control. 
 Fold change 
Compared to 
the YFP 
control 
Genes deregulated due to 
expression of HPIP-WT in hCB 
CD34
+
 cells relative to YFP 
Genes deregulated due to 
expression of ?NRPID-HPIP YFP 
in hCB CD34
+
 cells relative to 
YFP 
 
2 to 3 fold 
 
CXCL5, GZMB 
 
CXCL5 
 
1.5 to 2 fold 
 
EMP1 
 
PHLDA2, SCARNA17, CYP1A1 
TMEM107 
 
 
Down 
regulated 
gene 
expressions 
  
1 to 1.5 fold 
 
 
CD9, PNA3, PLTP, CARHSP1, 
G6PD, HEY1, NARG1, PECAM1, 
EXOSC4, HIST1H2BG, ELA2, 
HEATR2, CYB561, ACBD3, 
PRSS1, CTSL1, SPINK2,  17orf81, 
TMEM107, SGOL2, SCD, TGFBI, 
RTKN, SLC38A5 SCD5 
 
NR5A2, CD163, 229815_at, HBZ, 
KDELR3, SOS1, IGHM, UGT1A1, 
HIST1H2BG, CTHRC1, 28919_at, 
SLC22A18, RAP1A, CNN3, 
RBM6, HIST1H1C, PF4, BIN1, 
FGD5, CMTM5, SLC16A14, 
UGT1A6, 214349_at,  TGFB1I1, 
CD14, hCG_2045751, TNS1, 
 
2 to 3 fold 
 
FOS, ASS1, PBXIP1 
 
 
PBXIP1 
 
1.5 to 2 fold 
 
PTPRO, CHAC1, GLT25D2, 
SLC7A11, FLJ37034, DDIT4, 
CHRM3, FOSB, RPS15A, VLDLR 
 
DPP4 
 
 
Upregulated 
gene 
expression 
 
1 to 1.5 fold 
 
CCPG1, S100P, LOC641808, 
FLNA, RKHD2, TRIP12, CHD2, 
LOC643641, CXCL2, OGT, 
MAD1L1, MAP7D2, WARS, 
NFKBIZ, SFRS3, SLC16A3, ATF3, 
CTH, ST6GALNAC3, SFRS1, 
CD69, CNOT7, ANXA3, PLXNA1, 
PSAT1, HNRPA1, CTH, ASNS. 
SLC10A4, P2RY14, TNFRSF19, 
S100P, C3AR1, TSPAN4, 
CXCR4, CCL3, CCNA1, ENPP2, 
SGK, DLC1, IL1RL1,  NETO2, 
TRIB2, PPAP2A, RDH10, 
C5orf20, PKIB, SIGLEC6, 
KCTD12,  31628_s_at, 
MGC10850, RGS2, RPS15A, 
IL10RB, PTGS2, DLC1, HPGD, 
PTX3, EPC1, GLT25D2, FGFBP3, 
TRIM59, LMO4, C5orf5, HS2ST1, 
RNASE2 
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Table 4.10.1b. The table demonstrates some important differentially expressed genes within 
different pathways. 
Gene 
Name 
Function in brief 
  
FGFR3 Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1 
FLNA Anchors various transmembrane proteins to the actin cytoskeleton and serves 
as a scaffold for a wide range of cytoplasmic signalling proteins 
HRAS Ras proteins bind GDP/GTP and possess intrinsic GTPase activity 
SOS1 Promotes the exchange of Ras-bound GDP by GTP 
CXCR4  Receptor for the C-X-C chemokine CXCL12/SDF-1 
TNFRSF19 Can mediate activation of JNK and NF-kappa-B. May promote caspase-
independent cell death. 
CCL3 Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 
and CCR5. 
CXCL2 Hematoregulatory chemokine, which, in vitro, suppresses haematopoietic 
progenitor cell proliferation 
CXCL5 Involved in neutrophil activation 
PF4 Chemotactic for neutrophils and monocytes 
HGF Hepatocyte growth factor (HGF) regulates cell growth, cell motility, and 
morphogenesis by activating a tyrosine kinase signaling cascade after binding 
to the proto-oncogenic c-Met receptor 
 
IL10RB Receptor for IL10 and IL22. Serves as an accessory chain essential for the active 
IL10 receptor complex and to initiate IL10-induced signal transduction events 
WNT5B implicated in oncogenesis and in several developmental processes, including 
regulation of cell fate and patterning during embryogenesis. This gene is a 
member of the WNT gene family. 
ASS1 The protein encoded by this gene catalyzes the penultimate step of the arginine 
biosynthetic pathway. 
GZMB linked to an activation cascade of caspases (aspartate-specific cysteine 
proteases) responsible for apoptosis execution 
MLL Histone methyltransferase. Methylates 'Lys-4' of histone H3. H3 'Lys-4' methylation 
represents a specific tag for epigenetic transcriptional activation. Promotes 
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PPP1R15A-induced apoptosis. 
 
SCARNA17 small Cajal body-specific RNA 17 
DDIT4 DNA damage inducible transcript 4, inhibits cell growth by regulating the FRAP1 
pathway upstream of the TSC1-TSC2 complex 
DPP4 Plays a role in T-cell activation and human stem cell homing pathways. 
FOSB FosB interacts with Jun proteins enhancing their DNA binding activity 
 
 
 4.11. Gene expression profiling in leukaemia patient samples 
 
4.11.1. cDNA microarray analysis from AML samples and normal 
bone marrow from healthy donors.  
 
 To extend the analysis to primary AML samples bone marrow samples from 
147 thoroughly characterized patients with newly diagnosed and untreated AML as 
defined by the World Health Organization classification were used and processed 
immediately as described117,118 and compared to fresh bone marrow samples from 
healthy volunteers. Each AML subgroup comprises approximately 10 samples.  
 Samples were analyzed by cytomorphology, cytochemistry, 
immunophenotyping, cytogenetic, and molecular genetics in all cases and were 
characterized by specific chromosomal aberrations or molecular genetic alterations 
from the leukaemia diagnostics laboratory, Klinikum Großhadern, Munich. The 
studies were done in accordance with the rules of the local internal review board 
and the tenets of the revised Helsinki protocol. First cDNA micro arrays 
documented high expression of HPIP in AML patients with specific cytogenetic 
aberrations such as CALM/AF10 translocation, FLT3 length mutation or 
translocation t(15;17) compared to bone marrow from healthy donors as well as 
compared to other cytogenetic subtypes such as MLL-PTD, complex, AMLM2 
andM4Eo (Fig 4.11).  
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Figure 4.11: Expression levels of HPIP in cytogenetically different subgroups of patients 
with AML. Bone marrow samples from patients with newly diagnosed and untreated AML and 
fresh bone marrow samples from healthy volunteers were analyzed. Expression of HPIP was 
found to be significantly elevated in AML samples from patient carrying different cytogenetic 
aberrations especially CALM-AF10, AML-M3, AML-M2, AML-FLT3 (N=10, ***p?0.01) compared to 
healthy controls. Significance was determined by Student’s t-test and is indicated above in the 
box plots. The indicated statistically significant differences are in comparison to the normal bone 
marrow (indicated with red line), used as control. 
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5. Discussion 
 
 In the present study, the human PBX interacting protein (HPIP-WT) was 
characterized as a novel regulatory protein of human haematopoiesis. It was 
furthermore possible to demonstrate that the C´ terminal nuclear receptor/PBX 
interacting domain (NRPID), is a critical functional domain of HPIP-WT. All the data 
were obtained using the human haematopoietic stem cell functional assays.  
 
HPIP-WT is able to enhance the clonogenic progenitors in the liquid 
suspension cultures and colony forming assays 
 
 HPIP-WT has been reported previously as a novel PBX1 interacting protein. It 
can bind to the different members of the mammalian PBX family, inhibit the binding of 
PBX1/HOX complex to DNA and block the transcriptional activity of E2A-PBX.105 In 
the liquid suspension cultures, the expression of HPIP-WT on huCB derived CD34+ 
cells could significantly decrease the cell proliferation when compared to the control. 
One of the most striking effects in vitro was the significant increase in the number of 
BFU-E/CFU-E colonies, when compared to the control. The multi-potential 
progenitors (e.g. CFU-GEMM) and the lineage-committed progenitors (e.g. CFU-E, 
CFU-GM), representing various stages along the differentiation pathway, can be 
identified by in vitro assays and by the expression of known surface antigens.119,120 
 A selective increase in erythroid colonies compared with the control has been 
previously reported with the expression of HOXB4-WT in hCB CD34+ cells in the 
replating colony assays.121. As an interactor of the HOX co-factor PBX1 a similar 
effect was now seen for HPIP. It was previously shown that HOXB4 binds to PBX1, 
thus both proteins form complexes with PBX1. It remains open whether this impact on 
erythroid colony formation is linked to PBX1 protein complexes.  
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HPIP-WT is able to enhance the frequency and yield of the long term culture 
initiating cells in vitro, but does not increase the SCID Repopulating Cell (SRC) 
frequency in vivo. 
 
 A potential role of HPIP-WT in the regulation of most primitive haematopoietic 
cells was tested using long term culture initiating cell (LTC-IC) assay in vitro and the 
competitive repopulating unit (CRU) assay in vivo. The constitutive expression of 
HPIP- WT elevated the number of LTC-IC per million cells in vitro relative to the 
control YFP.  The result states that constitutive expression of HPIP-WT influences the 
growth kinetics of primitive progenitor cells on a larger scale, for example, by 
shortening the doubling time, or enhanced self-renewal of HSCs, as it has been 
implicated in the over expression model of HOXB4 and PBX1.79,121-123 Also in the 
competitive repopulating assays carried out in NOD/SCID mice using different limiting 
dilutions, we could observe a trend towards an increased frequency of SRC in the 
case of HPIP-WT as compared to the control, but without a statistical significance. 
Thus, again similar to HOXB4, HPIP can amplify primitive human progenitors at least 
in vitro, again suggesting that both proteins might have overlapping functions.   
 
HPIP-WT expression is able to increase the short term SCID repopulating cells 
(huST-SRCs) in vivo. 
 
 We further tested the effects of HPIP-WT expression on the huST-SRCs in the 
NOD/SCID xenotransplantation model. With the expression of HPIP-WT-YFP, the 
proportion of human cells expressing the hCD34+ and the early differentiation marker 
hCD38 (hCD34+38+ cells) was found to be significantly increased in the BM of the 
engrafted mice, relative to the control. This indicates that the HPIP-WT affects the 
human haematopoietic cells with short–term in vivo repopulating activity that has 
been defined before as the hSTRC population in vivo. These phenotypic separable 
populations of haematopoietic stem cells are pluripotent and capable of self renewal, 
and have been clearly identified in the engrafted NOD/SCID mice.31 This analysis 
elucidated a regulatory effect of HPIP-WT expression in the hST-SRCs in 
repopulating this particular HSC population.  
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HPIP-WT could alter the lympho/myeloid cell ratio in vivo. 
 The HPIP-WT expression also induced an alteration in the lympho/myeloid cell 
ratio with a shift towards the myeloid compartment that is characterized by expression 
of CD15 marker. This increase in the myeloid lineage cells did not come on expense 
of the lymphoid cells. The expression of HPIP-WT did not produce any changes in the 
lymphoid cell population (hCD19+) compartment, when compared to the control. This 
observation revealed that the expression of HPIP-WT is able to increase generation 
of myeloid cells in vivo without affecting the lymphoid cell compartment. Strikingly, it 
suggests that HPIP-WT expression does not interfere with the lineage determination 
of the early progenitor cells in vivo. This stands in contrast to HOXB4, which in the 
same setting does not influence lineage differentiation.  
 
HPIP-WT expression affects the expression of genes involved in the cell 
signalling and growth pathways.  
 
 In an affymetrix differential cDNA expression analysis, HPIP-WT expression in 
huCB CD34+ cells was able to up-regulate the expression of genes such as DDITP4, 
FLNA, FOSB and CXCL2 genes, relative to the control. The DDIT4 (DNA damage 
inducible transcript 4) expression can inhibit cell growth by regulating the FRAP1 
pathway.124,125 (CXCL2 is secreted by haematopoietic stem cells and it mobilizes cells 
by interaction with a cell surface chemokine receptor called CXCR2.126 CXCL2 has 
been implicated as a hematoregulatory chemokine that suppresses haematopoietic 
progenitor cell proliferation, in vitro.127 DDIT4 and CXCL2 up-regulation might 
contribute to the decreased proliferation of HPIP-WT-YFP+ cells in the liquid 
suspension cultures. However, it remains open why HPIP-WT expression increased 
the absolute number of clonogenic progenitors relative to the YFP control in liquid 
expansion cultures parallel to decreasing the proliferation of the bulk population in the 
suspension.   
 Previously in the literature HPIP-WT has been described as a scaffold protein 
that is able to tether the estrogen receptor-alpha (ESR1) to the microtubules and 
allows them to influence estrogen receptors-alpha signalling.107,108 HPIP induced 
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increased expression of FLNA (Flamin A), a protein which anchors various 
transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide 
range of cytoplasmic signalling proteins.128,129 Upregulation of FLNA could contribute 
to the changes in growth kinetics of the cells in the liquid suspension cultures. 
 The expression of HPIP-WT in primary cells, down regulated CXCL5, GZMB, 
TGFB1, and HEY1 genes in differential cDNA expression analysis relative to the 
control. TGFB1 is a multifunctional peptide that controls proliferation, differentiation 
and other functions in many cell types. It regulated the actions of many other growth 
factors and determines a positive or negative direction of their effects130. HEY1 gene 
encodes a nuclear protein belonging to the hairy and enhancer of split-related (HESR) 
family of basic helix-loop-helix (bHLH) type transcriptional repressors. Expression of 
this gene is induced by Notch and c-Jun signal transduction pathways.131-133 HPIP WT 
has also been implicated as an estrogen receptor-Interacting protein that not only 
activates MAPK and AKT pathways but also potentates’ estrogen-responsive gene 
expression in breast cancer cell lines.107,108 The genes that we have observed to be 
deregulated above are belonging to cytokine-cytokine interaction pathways (CXCL2, 
CXCL5) and MAPK (FLNA) pathways. This further indicates that HPIP-WT 
expression is able to affect important cell signalling pathways. 
 
HPIP-WT when expressed together with HOXB4-WT does not produce the 
synergistic effects on haematopoietic progenitors. 
 
 HPIP-WT is strongly expressed in the hCB CD34+ fraction containing the 
haematopoietic progenitors and at lower levels in the hCB CD34- fraction comprising 
the mature cell population. The same pattern of expression was found for PBX1, 
indicating that HPIP and PBX1 are co-expressed in the same human haematopoietic 
cell compartment. This expression level decreases with differentiation of the HSCs. 
The pattern of HPIP-WT expression is similar to the expression of other 
homeodomain genes such as HOXB4.105 or like ABCG transporters expression.134 
Among the best characterized co-factors of HOX genes are the mammalian pre-B cell 
leukaemia homeobox (Pbx)89 and the myeloid ecotropic viral insertion site (Meis)91 
family members.  
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 It is predicted that Hox and Pbx proteins interact within multiprotein complexes 
that have the highest level of specificity in terms of DNA binding and co-ordination of 
activation or repression events.82 In another attempt we tried to express both HPIP-
WT and HOXB4-WT proteins by making double transductions on hCB CD34+ using 
YFP and GFP reporters respectively. The hCB CD34+YFP+GFP+ cells were sorted 
out and in vitro CFC and LTC-IC assays were carried out. We did not observe any 
synergistic effects produced by both the proteins together. We did see a trend 
towards the increased CFC numbers in this case but is was statistically non 
significant relative to control. Sustained in vitro trigger of self-renewal divisions in 
Hoxb4hiPbx1 haematopoietic stem cells has been already been implicated.135 Also, 
genetic interactions between two well-recognized regulators of this process: Bmi1 and 
Hoxb4, using complementation and over expression strategies in mouse HSCs, are 
well documented.136 
 Our results do not formally exclude functional collaboration between HPIP-WT 
and HOXB4-WT: it might be that endogenous HOXB4-WT is sufficient for an optimal 
effect of HPIP-WT and that over expression of HOXB4 is not able to further augment 
the impact of HPIP-WT on early progenitor cells. Another hypothesis could be that the 
role of HPIP-WT protein and its collaboration is not extended to HOXB4; however we 
do not have enough evidence to show that at present. 
  
Importance of the functional domains of HPIP-WT 
 
 Next we were interested in the functional domains of HPIP. The mutant form 
?NRPID-HPIP-YFP is unique in a way that a set of 3 amino acids between position 
615aa-619aa (deletion between 1845 bp-1857 bp on cDNA) was deleted artificially. 
This region has been implicated as a partial part of the ‘PBX binding Domain’ (PBD 
position 560aa-633aa; Abramovich et al, 2002) and also as a nuclear receptor 
interacting domain (C-terminal LXXLL motif position 615aa-619aa). The LXXLL-type 
motifs have been shown to mediate the receptor interactions of co activators and 
corepressors.137,138 
 This mutant was generated to understand if a deletion in nuclear receptor/PBX 
binding domain could affect the expression or normal function of HOX or Para HOX 
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genes. Since we understand that this particular region is interacting with PBX and the 
protein is a regulator of pre-B-cell leukaemia transcription factors (PBX) function. It 
has been shown to inhibit the binding of PBX1-HOX complex to DNA and to block the 
transcriptional activity of E2A-PBX1.105. We have hypothyzed that a deletion in such a 
region could probably affect the stem cell fate. Previously similar cases have been 
shown for Hox genes like preferential targeting of a small region in the Hoxa gene 
locus in E2A-PBX1-induced lymphoid leukaemia resulting in the over expression of 
several Hoxa genes.139 
 The second mutant ?MBR-HPIP-YFP has a deletion mutation in the 
microtubule binding sequence (putative leucine repeat rich motif, LRR, position of 
motif spanning between 576 bp-654 bp (190aa-218aa) in the cDNA; 
LxxxLNxxLLxxLxLLxLxxLL), where a set of 20 amino acids was removed to disrupt 
the hydrophobic core of the HPIP-WT protein. This region has been implicated in 
association of HPIP to cytoskeletal fibers. Leucine-rich repeats (LRRs) are 20-29aa 
residue sequence motifs, present in a number of proteins with diverse functions. The 
primary function of these motifs is to provide a versatile structural framework for the 
formation of protein-protein interactions.140 
 A number of human diseases have been shown to be associated with mutation 
in the genes encoding leucine-rich-repeat (LRR)-containing proteins.141 Protein 
localization at the sub cellular level was investigated using flag antibody and the 
images were captured using confocal microscope. Visibly there was no change in 
localization of WT and mutant form of HPIP proteins at the sub cellular level, stating 
that the deletions did not effect the distribution of the protein at the sub cellular level. 
 
The NRPID mutant abrogates the effects of wild type HPIP and induces a 
replating capacity in the colony forming assays. 
 
 In the colony forming assays, the deletion of NRPID in HPIP-WT led to the 
increase in the number of colonies consisting of multilineage committed progenitors 
(CFU-GEMM/CFU-GM). The expression of the NRPID mutant did not show increase 
in the number of erythroid (BFU/CFU-E) colonies relative to the YFP control; this is in 
complete contrast to the results obtained with HPIP-WT relative to the YFP control.   
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This indicates an apparent role of HPIP-WT at committed human haematopoietic 
progenitor level. The mutation of LXXLL motifs can prevent essential activated 
complex formations and eliminate activation of pathways such as in the case of 
Estrogen Receptor-Modulator of Nongenomic Actions of Estrogen Receptor (ER-
MNAR) complex formation and its effects on the Src/ Mitogen Activated Protein 
Kinases (Src/MAPK) pathway.142 Furthermore the role of Ras and MAP kinases 
(MAPKs) in the regulation of erythroid differentiation has been demonstrated.143-145 
 In addition a serially replatable potential was observed in the colony forming 
cells transduced with ?NRPID-HPIP-YFP, in contrast to the CFCs transduced with 
HPIP-WT or ?MBR-HPIP-YFP. This suggests that the domain deleted in the ?NRPID-
HPIP mutant might be important for the self – renewal program of early human 
progenitors. In the differential gene expression analysis, the expression of ?NRPID-
HPIP-YFP up regulates expression of WNT5B gene, relative to HPIP-WT and also 
the control YFP. The Wnt family genes are implicated as the genes involved in the 
regulation of self renewal of stem cells (Willert K, 2003, Reya T, 2003). The up 
regulation of WNT5B in ?NRPID-HPIP-YFP+ cells explains the enhanced replating 
capacity of the clonogenic progenitors in this case, relative to the control. A number of 
other transcription factors have also been suggested to be involved in HSC self-
renewal, including the over expression of HOXB4.79, activation of NOTCH.146 and 
knockout of BMI1 147,148 
 
NRPID mutant does not affect the human short term SCID repopulating cells 
(hST-SRCs) in the NOD/SCID model  
 A sharp decrease in the proportion of hCD34
+
38+ cells was observed in the 
BM of the mice transplanted with ?NRPID-HPIP-YFP+ cells, when compared to the 
HPIP WT+ cells. However, no significant changes were observed relative to the 
control YFP. The hCB CD34+38+ cell population in the BM of NOD/SCID mice have 
been characterized as a set of short term repopulation cells (hSTRCs), with higher 
erythroid and megakaryocytic lineage growth properties (hSTRC-M). We also looked 
for the changes in the proportion of hCD34+38- cells, i.e. hSRTC-LM population with 
broader lympho-myeloid differentiation potential149, with the expression of ?NRPID-
HPIP-YFP. The hST-SRCs were significantly lower in number with NRPID mutant 
Discussion 
 107 
 
 
expression as compared to HPIP-WT and control YFP. This reveals that the deletion 
of nuclear receptor interacting domain from the HPIP-WT protein radically affects the 
hSTRC-LM. 
  
NRPID mutant decreases the proportions of lymphoid and myeloid cell 
compartments in vivo 
 
 The hCBC45+?NRPID-HPIP-YFP+-SRCs showed a significant decrease in the 
myeloid (hCD15) and lymphoid (hCD19) cell compartments, relative to HPIP-WT and 
control. The result directly indicates that the nuclear receptor/PBX binding domain of 
HPIP-WT is functionally essential for normal function of HPIP-WT in haematopoietic 
progenitor fate. The role of nuclear receptor/PBX interacting domain of HPIP could 
play a role in the normal functions of PBX in HSCs. Studies of Pbx1-/- mutant mice 
have revealed that Pbx1 is also required for the generation of common lymphoid 
precursors of B, NK (natural killer) and T cells.150.  
 In the affymetrix gene expression data, gene groups showing preferential 
expression in quiescent and normal dividing cells could be observed as deregulated 
in ?NRPID-HPIP+ cells relative to the control YFP. The genes involved in cytokine-
cytokine interactions were found to be differentially expressed: CCL3, CXCL2, 
CXCL5, CXCR4, HGF, IL10RB, PF4 and TNFRSF19. The result also points towards 
a possible role played by the deregulated cytokine-cytokine interactions pathway in 
the decreased cell proliferation of the ?NRPID-HPIP+ cells relative to the control 
YFP.151,152  
 
NRPID mutant expression up regulates the expression of CXCR4 gene and 
reduces the engraftment levels of the HSCs in NOD/SCID mice. 
 The NRPID mutant expression decreased the human cell engraftment into 
NOD/SCID mice. Of 31 mice that received a transplant, only 9 mice (29%) exhibited 
human cell engraftment after 6-8 weeks and the engraftment levels were low 
(medien=1.9% CD45+ cells, p<0.05) relative to the HPIP-WT, with 31 mice engrafted 
out of 65 mice (47%) and YFP control with 32 mice engrafted out of 53 (60). This low 
engraftment of ?NRPID-HPIP–YFP+ cells could result from an impaired migration or 
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their reduced capacity to establish human haematopoiesis (requires proliferation and 
differentiation in the bone marrow environment) 153,154 
 The Affymetrix differential gene analysis data in the present study revealed 
the upregulated expression of CXCR4 and DPP4 in hCB CD34+ cells transduced 
with ?NRPID-HPIP–YFP cells in vitro, 1.5 fold increase in expression as compared 
to control YFP. The chemokine stromal cell-derived factor-1 (SDF-1) and its 
receptor CXCR4 are stated to be critical for murine bone marrow engraftment by 
human severe combined immunodeficient (SCID) repopulating stem cells. The 
CXCR4 ligand SDF-1á is a locally secreted small cytokine and is expressed 
constitutively in some tissues, including bone marrow and lung, which are major 
homing organs for metastatic breast cancer.155 CXCR4 is required for invasion, 
migration, and adhesion activities under SDF-1á-stimulated conditions, suggesting 
that CXCR4 may play a role in these steps toward malignant metastases.156  
 Treatment of human cells with antibodies to CXCR4 has been shown to 
prevent engraftment.157-159 Despite of the fact that CXCR4 is up regulated in the 
?NRPID-HPIP–YFP+ cells, the engraftment capacity did not increase. This affect 
can be explained with a decreased proliferation and differentiation for ?NRPID-
HPIP–YFP+ cells in bone marrow niches. This is a possible reason for the fact that 
?NRPID-HPIP–YFP+ cells could not reconstitute an efficient human haematopoietic 
system in NOD/SCID mice. 
 
The expression of NRPID mutant deregulates important genes relative to HPIP 
WT. 
 
 While analysing the differentially expressed genes between the expression 
profiles of the CB transduced with HPIP-WT and NRPID-HPIP mutant form, we could 
observe many important genes differentially expressed. Amongst them are BLNK (B-
cell adapter containing a SH2 domain protein), HEY1 (Tumour suppressor gene), 
PPAP2A (Major enzyme responsible of dephosphorylating LPA in platelets), CCL3 
(Chemokine), ZNF618, GZMB, IL1RL1, and CCNA1 (cell cycle regulatory gene) that 
are up-regulated in the case of ?NRPID-HPIP compared with HPIP-WT. The BLNK 
(SLP-65) protein has a function in the pre-BCR-signalling pathway, which constitutes 
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a critical developmental checkpoint in the B cell differentiation.160 Up-regulated genes 
such as BLNK can explain the differences observed with the reduced expansion of 
the lymphoid compartment with expression of NRPID mutant relative to the HPIP-WT, 
in vivo.  
 Another set of genes down-regulated in the case of NRPID-HPIP compared 
with HPIP-WT were: TGFB1I1, CHRM3, TNS1 (Src homology 2 domain protein, that 
is often found in molecules involved in signal transduction), SCARNA17 (small Cajal 
body-specific RNA 17), ASNS (Cell cycle control protein TS11), and CYP1A1 
(cytochrome P450 superfamily of enzymes), Amongst the down regulated genes in 
the above case, TNS1 gene is an actin binding protein and may be involved in linking 
signal transduction pathways to the cytoskeleton.161 Affymetrix differential expression 
analysis also demonstrated deregulated expression of three MAPKs pathway genes 
in the case of NRPID mutant, namely: CD14, FGFR3, and RAPIA. The result 
indicates that loss of the functional nuclear receptor/PBX interacting domain (LXXLL) 
of HPIP WT is associated with altered expression of MAPKs.  A direct role of HPIP in 
signal transduction pathways can be suspected with this data. 
 
Expression of HPIP is elevated in CALM/AF10 and FLT3 length mutation 
specific cytogenetic subtypes of AML. 
 
 The Affymetrix expression data from AML patient samples indicates that HPIP 
WT is highly expressed in selected subtypes of AML. AML cases with  specific 
cytogenetic aberrations such as the CALM/AF10 translocation, FLT3 length mutation 
or translocation t(15;17) had higher levels of HPIP expression as compared to the 
bone marrow from healthy donors as well as compared to other cytogenetic subtypes 
such as MLL-PTD, complex karyotype, AMLM2 and M4Eo. It has been shown that 
the MLL protein binds to the promoter of Hox genes to maintain their expression. MLL 
fusion proteins have also been reported to directly up regulate the Hox genes along 
with expression of co-factor Meis1. We analysed the expression of HPIP in a group of 
ALL-MLL patients, however there was no differences of HPIP expression compared 
to the normal bone marrow control.  
 Our data has clearly pigeonholes HPIP-WT as a novel regulator/mediator of 
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human haematopoietic stem cells with an important C´terminal nuclear receptor/PBX 
interacting domain. Expression of HPIP-WT promotes the growth and repopulation of 
clonogenic progenitors and long term culture initiating cells in vitro. It is also able to 
promote the expansion of hST-SRCs in vivo. It was able to effect the expression of 
important genes involved in cell signalling, cell cycle, proliferation and differentiation. 
We could demonstrate the importance of HPIPs´ nuclear receptor/PBX interacting 
domain in self renewal, hST-SRCs-LM cell compartment, lymphoid/myeloid and 
erythroid cell differentiation and its effects on the expression of genes involved in cell 
signalling, self renewal and engraftment/migration in NOD/SCID mice. However, there 
is still a need to further describe the molecular mechanisms which are underlying the 
regulatory role of HPIP in early human haematopoiesis.   
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6. Summary 
 The characterization of new genes involved in the regulation of 
normal/leukaemia haematopoiesis and the development of therapies against 
deregulated processes in haematopoiesis are the major goals in experimental and 
clinical haematology. The focus of this thesis was the characterization of 
haematopoietic PBX-interacting protein (HPIP), a novel putative regulatory protein 
of early human haematopoiesis. Using complex in vitro and in vivo assays we 
analyzed the impact of constitutive expression of HPIP- WT and its functional 
domains (nuclear receptor/PBX interacting domain and microtubule interacting 
domain) on the stem cell and early human haematopoietic development. To detect 
the affect of WT and mutated HPIP on the clonal progenitor cells, primary and 
secondary colony-forming-unit (CFC) assays were performed. Additionally the in 
vitro equivalent of HSC long-term culture initiating cells was detected with the 
(LTC-IC) assay. 
 We were able to show that the constitutive expression of HPIP-WT increases 
the number of cells detected on the level of committed clonogenic progenitors and 
long term culture initiating cells in the LTC-IC assays. In addition, HPIP-WT+ cells 
show enhanced number of CFCs generated per LTC-IC as compared to the 
control. Besides its effect on maintenance of primitive haematopoietic progenitor 
cells, constitutive expression of HPIP-WT could not block terminal haematopoietic 
differentiation. It also increases the proportions of the short term SCID repopulating 
cells (ST-SRCs, hCD34+38+) in vivo, when compared with the empty vector control. 
Additionally we could show that the constitutive expression of HPIP leads to an 
increase of myeloid cells in transplanted in the NOD/SCID mice. These data 
characterizes HPIP-WT as a novel regulator of the early human haematopoietic 
stem cells, whose constitutive expression has a notable impact on the short term 
committed progenitors and myeloid cell repopulation of human haematopoietic 
system.  
 We could further characterize the functional domains of HPIP-WT. We could 
demonstrate the importance of HPIPs´ nuclear receptor/PBX interacting domain in 
self renewal, hST-SRCs-LM cell compartment (ST-SRCs, hCD34+38+) in vivo, 
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lymphoid/myeloid and erythroid cell differentiation and its effects on the expression 
of genes involved in cell signalling, self renewal and engraftment/migration in 
NOD/SCID mice. Overall HPIP is a very important interactor of para HOX gene 
PBX. In the present study we could clearly prove it for the first time that HPIP´s 
expression in hu CD34+ cells holds an important role in the regulation of human 
haematopoiesis. 
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7. Zusammenfassung 
 Die Charakterisierung neuer Gene, die in die Regulation der 
normalen/leukämischen Hämatopoese involviert sind,  und die Entwicklung von 
Therapien gegen deregularisierte Prozesse in der Hämatopoese sind die 
Hauptziele der experimenteller und klinischer Hämatologie. Der Schwerpunkt 
dieser Promotionsarbeit war die Charakterisierung des hämatopoetischen PBX-
interacting Protein (HPIP), einem neuartigen mutmaßlichen regulatorischen Protein 
der frühen menschlichen Hämatopoese. Indem komplexe in vitro und in vivo 
Assays genutzt wurden, analysierten wir die Auswirkungen der konstitutiven 
Expression von HPIP-WT und seiner funktionalen Domänen (Kernrezeptor/PBX-
interagierende Domäne und Mikrotubuli  interagierende Domäne) auf die 
Stammzelle und frühe menschliche hämatopoetische Entwicklung. Um die 
Auswirkung von WT und mutierter HPIP auf klonale Vorläuferzellen zu erkennen, 
wurden primäre und sekundäre koloniebildende Einheiten (CFC) Assays 
durchgeführt. Zusätzlich wurde das in vitro Äquivalent von HSC, die Langzeitkultur 
initiierenden Zellen, nachgewieser mit dem sog. LTC-IC Assay. 
  Wir waren in der Lage zu zeigen, dass der konstitutive Ausdruck von HPIP-
WT die Anzahl der Zellen erhöht, die auf der Ebene der beteiligten klonalen 
Vorläuferzellen und Langzeitkultur initiierenden Zellen in den LTC-IC Assays 
erhöht. Weiterhin zeigen HPIP-WT*-Zelllen eine vergrößerte Anzahl von CFC, die 
per LTC-IC generiert wurden, als die Kontrolleinheit.  Abgesehen von seiner 
Auswirkung auf die Aufrechterhaltung primitiver hämatopoetischer Vorläuferzellen, 
konnte die konstitutive Expression von HPIP-WT die abschließende 
hämatopoetische Differenzierung nicht blockieren. Sie erhöht außerdem die 
Proportionen von kurzfristig SCID wiedervermehrten Zellen (ST-SRCs, 
hCD34*38*) in vivo im Vergleich zur leeren Vektorkontrolleinheit. Zusätzlich 
konnten wir zeigen, dass die konstitutive Expression von HPIP zu einer Erhöhung 
der myeloiden Zellen führt, wenn sie NOD/SCID-Mäusen transplantiert werden. 
Diese Daten charakterisieren HPIP-WT als einen neuen Regulator der frühen 
menschlichen hämatopoetischen Stammzelle, dessen konstitutive Expression 
einen beträchtlichen Effekt auf die kurzzeitig agierenden Vorläuferzellen und die 
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Repopulation der myeloiden Zellen des menschlichen hämatopoetischen Systems 
hat.  
 Darüber hinaus konnten wir die funktionalen Domänen des HPIP-WT 
charakterisieren. Wir konnten die Bedeutung des Kernrezeptors von HPIP/PBX-
interagierender Dömane in Hinsicht auf die folgenden Bereiche zeigen: 
Selbsterneuerung, hST-SRCs-LM Zellabschnitt (ST-SRCs, hCD34+38+) in vivo; 
lymphoider/myeloider and erytroider Zelldifferentiation und seiner Auswirkungen 
auf die Expression von Genen, die bei der Zellsignalgebung, Selbsterneuerung 
und Anwachsen/Migration bei NOD/SCID-Mäusen beteiligt sind. Das umfassende 
HPIP ist ein sehr wichtiger interagierendes Element des para HOX-Gens PBX. In 
der vorliegenden Studie konnten wir erstmalig eindeutig beweisen, dass die 
Expression von HPIP in humanen CD34*-Zellen eine bedeutende Rolle in der 
Regulation der menschlichen Hämatopoese spielt. 
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9. Abbreviations 
• μl   Microliter 
• μM   Micromola 
• ALL   Acute lymphoid leukemia 
• AML   Acute myeloid leukemia 
• BFU-E   Burst forming unit- Erythroid 
• BM   Bone marrow 
• CB   Cord blood 
• CD   Cluster of Differentiation 
• CFC   Colony forming cell 
• CSF   Colony stimulating factor 
• DMSO   Dimethylsulfoxid 
• DNA   Desoxyribonucleic acid 
• EPO   Erytropoietin 
• FAB   French American British 
• FACS   Fluoresence Activated Cell Sorting 
• FISH   Flurecence in situ hybridisation 
• FLT3   FMS-like tyrosine kinase 3 
• G-CSF    Granulocite-Colony stimulating factor 
• GM-CSF  Gramulocite-Macrophage-Colony stimulating factor 
• HB   Homeobox gene 
• HD   Homeodomain 
• IL   interlulukin 
• ITD   Internal tandem duplication 
• LDA-LTC-IC  Limiting dilution assay LTC-IC 
• LM   Lenght mutation 
• LTC-IC   Long-term culture-initiating cell 
• LTR   Long terminal repeat 
• M-CSF   Macrophage-Colony stimulating factor 
• MIG   MSCV-IRES-EGFP 
• MNC    Mononuclear cells 
• MSCV   Murine Stem Cell Virus 
• NBM   Normal bone marrow 
• NOD/SCID  Non Obese Deficent-Sever Compromise Immuno 
Deficent   
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• PB   Peripheral blood 
• PCR   Polymerase Chain Reaction 
• PI   Propidium iodide 
• PTK   Phospho tyrosine kinase 
• PTK   Protein Tyrosine Kinase 
• PTKI   Protein Tyrosine Kinase Inhibitor 
• RNA   Ribonucleic acid 
• S-CFU-S  Spleen-Colony forming unit 
• SC-IC   Suspension culture- initiating cell 
• SEM   Standard error of the mean 
• t    translocation 
• TDK   Tyrosine kinase domain 
• TM   Transmembrane domain 
• VCM   Virus containing medium 
• WBC   White blood cell 
• WT   Wild type 
• YFP   Yellow Fluorescent Protein 
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